[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 184
1. Connolly G, Wladis E, Masselam K, Weinberg DA: Contralateral orbital melanoma 28 years following enucleation for choroidal melanoma. Orbit; 2007 Dec;26(4):291-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contralateral orbital melanoma 28 years following enucleation for choroidal melanoma.
  • A 79-year-old man underwent right enucleation for a choroidal melanoma.
  • Orbital imaging revealed a large left lateral orbital mass, extending back to the orbital apex, which was found on subtotal resection to represent an orbital melanoma.
  • Skin survey was negative, and the prior right choroidal melanoma was the most likely metastatic source.
  • He underwent radiotherapy of the residual tumor at the left orbital apex, as well as radiotherapy of small liver and lung nodules felt to likely represent metastatic melanoma.
  • While melanoma is often considered a highly malignant and lethal tumor, some melanomas are characterized by a more benign course.
  • [MeSH-major] Choroid Neoplasms / pathology. Melanoma / secondary. Orbital Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097971.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Kitahara S, Morikawa S, Shimizu K, Abe H, Ezaki T: Alteration of angiogenic patterns on B16BL6 melanoma development promoted in Matrigel. Med Mol Morphol; 2010 Mar;43(1):26-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration of angiogenic patterns on B16BL6 melanoma development promoted in Matrigel.
  • Because the progression and metastasis of solid tumors depend on their local microcirculation, we sought to characterize tumor angiogenesis three dimensionally in a highly metastatic mouse melanoma model, B16BL6 (B16), injected with Matrigel into the subcutis in the skin on the back of syngeneic C57BL/6 mice.
  • [MeSH-major] Melanoma, Experimental / blood supply. Melanoma, Experimental / pathology. Neovascularization, Pathologic / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] News Physiol Sci. 2003 Apr;18:65-70 [12644622.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45826-32 [12954626.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):15240-8 [11278365.001]
  • [Cites] Science. 2008 Apr 4;320(5872):38-41 [18388269.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2520-6 [10811134.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1363-80 [10751361.001]
  • [Cites] Am J Physiol. 1996 Dec;271(6 Pt 2):H2547-62 [8997316.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • [Cites] J Pathol. 1996 Apr;178(4):363-6 [8691311.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):422-33 [12778132.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2173-80 [16489018.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):739-52 [10487832.001]
  • [Cites] Nat New Biol. 1973 Apr 4;242(118):148-9 [4512654.001]
  • [Cites] Chest. 2005 Dec;128(6 Suppl):602S-608S [16373858.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1991;418(2):111-7 [1899955.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2043-55 [11395382.001]
  • [Cites] Science. 1999 Jun 18;284(5422):1994-8 [10373119.001]
  • [Cites] Microvasc Res. 2006 Mar;71(2):69-75 [16545400.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8249-55 [15548691.001]
  • [Cites] Am J Pathol. 2007 Jan;170(1):1-15 [17200177.001]
  • [Cites] Microvasc Res. 2007 Sep-Nov;74(2-3):85-9 [17602710.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Apr;54(1):53-61 [15780907.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1801-15 [14578181.001]
  • [Cites] J Biol Chem. 1992 Jun 5;267(16):10931-4 [1375931.001]
  • [Cites] Biochemistry. 1982 Nov 23;21(24):6188-93 [6217835.001]
  • [Cites] J Pathol. 2002 Jul;197(3):355-62 [12115882.001]
  • [Cites] Med Mol Morphol. 2005 Mar;38(1):36-42 [16158178.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):985-1000 [11891196.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Sep;287(3):C572-9 [15308462.001]
  • [Cites] Lab Invest. 1990 Jul;63(1):115-22 [1695694.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):789-96 [11238026.001]
  • [Cites] Int J Cancer. 1985 Jan 15;35(1):107-11 [3881360.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):489-502 [17717633.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):411-21 [12778131.001]
  • [Cites] Virchows Arch. 2006 Jun;448(6):768-75 [16612622.001]
  • [Cites] Mol Aspects Med. 2002 Dec;23(6S):S1-27 [12537983.001]
  • (PMID = 20340003.001).
  • [ISSN] 1860-1499
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biocompatible Materials; 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen
  •  go-up   go-down


3. Forman SB, Vidmar DA, Ferringer TC: Collision tumor composed of Merkel cell carcinoma and lentigo maligna melanoma. J Cutan Pathol; 2008 Feb;35(2):203-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor composed of Merkel cell carcinoma and lentigo maligna melanoma.
  • We report the case of an immunocompetent 79-year-old white man with a history of melanoma in situ on the back with a collision tumor composed of a Merkel cell carcinoma (MCC) and lentigo maligna melanoma on the left cheek.
  • The atypical melanocytes of lentigo maligna melanoma expressed Melan-A and S-100.
  • Prior reports of MCC in collision with non-melanoma skin cancers are reviewed.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Hutchinson's Melanotic Freckle / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Lentigo maligna melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190446.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


Advertisement
4. Gillgren P, Brattström G, Frisell J, Persson JO, Ringborg U, Hansson J: Effect of primary site on prognosis in patients with cutaneous malignant melanoma. A study using a new model to analyse anatomical locations. Melanoma Res; 2005 Apr;15(2):125-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of primary site on prognosis in patients with cutaneous malignant melanoma. A study using a new model to analyse anatomical locations.
  • The prognostic impact of different anatomical sites in patients with cutaneous malignant melanoma (CMM) has been widely debated and requires further elucidation.
  • There was a significantly increased risk of CMM-specific death in patients with a primary tumour site in the middle and lower back (HR=1.8, P=0.04) and in the supramammary and mammary area (HR=1.8, P=0.05).
  • When all areas were analysed in pairs, the dorsal shoulder, superior back and clavicular area also showed a worse prognosis.
  • It can be concluded that the tumour site is of prognostic importance, and that the middle and lower back and supramammary and mammary areas are independent factors related to a poor prognosis.
  • [MeSH-major] Melanoma / mortality. Skin Neoplasms / mortality
  • [MeSH-minor] Aged. Diagnosis, Computer-Assisted / methods. Female. Follow-Up Studies. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / pathology. Humans. Imaging, Three-Dimensional. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasms, Multiple Primary / ultrastructure. Prognosis. Proportional Hazards Models. Software. Survival Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15846146.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


5. Ferrara G, Giorgio CM, Zalaudek I, Broganelli P, Pellacani G, Tomasini C, Argenziano G: Sclerosing nevus with pseudomelanomatous features (nevus with regression-like fibrosis): clinical and dermoscopic features of a recently characterized histopathologic entity. Dermatology; 2009;219(3):202-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Sclerosing nevi with pseudomelanomatous features or, else, nevi with regression-like fibrosis (NRLF) are histopathologic simulators of regressing melanoma.
  • Thirty-seven lesions were excised from the back, mostly from the scapular area.
  • CONCLUSION: NRLF are mostly found in the convex area of the back.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Fibrosis / pathology. Follow-Up Studies. Humans. Male. Melanocytes / pathology. Melanoma / diagnosis. Middle Aged. Sclerosis / pathology. Young Adult

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 S. Karger AG, Basel.
  • (PMID = 19590167.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


6. Zeren-Bilgin I, Gür S, Aydin O, Ermete M: Melanoma arising in a hairy nevus spilus. Int J Dermatol; 2006 Nov;45(11):1362-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma arising in a hairy nevus spilus.
  • Cutaneous melanoma may develop de novo on normal skin or in contiguity with a potential melanocytic precursor.
  • Physical examination revealed a 10x18-cm lesion with speckled lentiginous pigmentation and terminal hairs on the lower back.
  • Histopathological evaluation of the nevus and the suspicious nodule revealed the characteristics of a melanocytic nevus and melanoma, respectively.
  • This case report is a reminder that there may be great variation in the clinical appearance of nevus spilus, and thus dermatologists must be aware of these lesions as potential precursors of malignant melanoma.
  • [MeSH-major] Lentigo / complications. Melanoma / etiology. Skin Neoplasms / etiology

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076727.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. de Leeuw J, van der Beek N, Neugebauer WD, Bjerring P, Neumann HA: Fluorescence detection and diagnosis of non-melanoma skin cancer at an early stage. Lasers Surg Med; 2009 Feb;41(2):96-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence detection and diagnosis of non-melanoma skin cancer at an early stage.
  • BACKGROUND: The occurrence of non-melanoma skin cancer (NMSC), including actinic keratosis (AK) is increasing all over the world.
  • The detection and diagnosis of NMSC is not optimal in clinical practice.
  • OBJECTIVE: The purpose of the present study was to use a large area skin fluorescence detection system to detect early NMSCs (clinical visible as well as non-visible lesions) in the face, neck, chest, back and hands of patients treated with UV and outdoor workers.
  • RESULTS: In 93 consecutively referred patients positive skin fluorescence was detected in 61 patients.
  • After histological examination the positive fluorescence appeared to be correlated to benign lesions in 28 patients (sebaceous gland hyperplasia in 22 patients) and to (pre-) malignant lesions in 33 patients (actinic keratosis in 29, BCC in 3 and SCC in 1 patient).
  • In five patients the FD technique used in this study appeared to be more sensitive for the identification of (pre-) malignant lesions than the clinical examination.
  • CONCLUSION: Diagnostic skin fluorescence using liposomal encapsulated 5-ALA and a specialised computerised detection and visualisation system offers the possibility for detection of NMSC at an early, pre-clinical stage.
  • The technique is well suited to examine large areas of skin.
  • It also identifies areas of most interest for performing confirmatory skin biopsies, as well as pre-operative assessment of boundaries of skin malignancies, and finally, the technique is applicable in the control and follow-up of skin cancer treatment.
  • [MeSH-major] Early Detection of Cancer. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19226578.001).
  • [ISSN] 1096-9101
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


8. de Maleissye MF, Beauchet A, Aegerter P, Saiag P, Mahé E: Parents' attitudes related to melanocytic nevus count in children. Eur J Cancer Prev; 2010 Nov;19(6):472-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sun exposure, fair phototype, and a high common melanocytic nevus (MN) count have been identified as the most important risk factors for melanoma.
  • MN are mainly acquired during childhood, and their relationship to sun exposure, sunburn, and light skin complexion is well documented.
  • Trained nurses counted the MN on each child's back and arms, depending on their size.
  • Multivariate analysis showed that the childhood MN count was linked to fair phenotype--fair skin: rate ratio (RR)=3.80, 95% confidence interval (CI)=2.25-6.41; blue/green eyes: RR=1.2, 95% CI=1.11-1.34; blond hair: RR=1.25, 95% CI=1.10-1.41; history of sunburn: RR=1.13, 95% CI=1.03-1.23, seaside sun exposure--RR=1.14, 95% CI=1.01-1.28, and to their parents' behaviors during exposure to the sun--increase in the number of MN when parents used sunscreen: RR=1.23, 95% CI=1.08-1.40; decrease in MN count when parents wore a tee-shirt: RR=0.86, 95% CI=0.79-0.93.
  • [MeSH-major] Attitude to Health. Melanoma / prevention & control. Nevus, Pigmented / prevention & control. Skin Neoplasms / prevention & control

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736840.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Sunscreening Agents
  •  go-up   go-down


9. Lykke J, Hansen MB, Ovesen H, Meisner S: [Capsule endoscopy detection of metastasis of a malignant melanoma in the small intestine]. Ugeskr Laeger; 2006 Oct 9;168(41):3533-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Capsule endoscopy detection of metastasis of a malignant melanoma in the small intestine].
  • We report a case of a 74-year-old man with a Clark's level II, 2.5 mm melanoma on his back that was excised.
  • Histological diagnosis showed metastatic malignant melanoma.
  • We believe that video capsule endoscopy may increase the rate of diagnosis of small-bowel melanoma metastases.
  • [MeSH-major] Endoscopy, Gastrointestinal. Intestinal Neoplasms / secondary. Melanoma / secondary
  • [MeSH-minor] Aged. Capsules. Gastrointestinal Hemorrhage / diagnosis. Humans. Intestine, Small / pathology. Male. Skin Neoplasms / pathology. Video Recording

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059809.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Capsules
  •  go-up   go-down


10. Chiu V, Won E, Malik M, Weinstock MA: The use of mole-mapping diagrams to increase skin self-examination accuracy. J Am Acad Dermatol; 2006 Aug;55(2):245-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of mole-mapping diagrams to increase skin self-examination accuracy.
  • BACKGROUND: Monthly skin self-examination (SSE) is associated with reduced incidence of advanced melanoma, but SSE is prone to error in detecting early changes of melanoma.
  • LIMITATIONS: This study was limited by sample size, only addressed lesions on the back, and did not involve actual melanomas in study participants.
  • CONCLUSIONS: Mole-mapping diagrams may improve SSE accuracy, and may be useful as a simple, cost-effective intervention in reducing melanoma mortality.
  • [MeSH-major] Melanoma / diagnosis. Self-Examination / standards. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844506.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA106592
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


11. White N, Yap LH, Srivastava S: Lymphadenectomy for melanoma in the clinically N1 neck: radical, modified radical, or selective? J Craniofac Surg; 2009 Mar;20(2):385-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphadenectomy for melanoma in the clinically N1 neck: radical, modified radical, or selective?
  • An analysis was made of 37 consecutive patients with melanoma for an 8-year period presenting with a clinically N1 neck (a single involved node based on clinical examination and radiologic investigation).
  • There was a mean follow-up of 3 years 10 months after primary diagnosis.
  • We would recommend a modified radical neck dissection for the N1 neck in melanoma with an intraoperative decision being made on which structures to preserve based on position of involved lymph node and adjacent structures, particularly in younger patients.
  • A selective neck dissection should be considered in those patients with significant comorbidity, distant metastatic disease, or primary sites on the back or posterior scalp.
  • [MeSH-major] Head and Neck Neoplasms / surgery. Lymph Node Excision / methods. Melanoma / surgery. Neck Dissection / classification

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258904.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Wu J, Rosenbaum E, Begum S, Westra WH: Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. Am J Dermatopathol; 2007 Dec;29(6):534-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The BRAF mutation is common in melanomas, but variation in rates across melanoma subtypes points to a complex interplay between BRAF activation and other factors (eg, sun exposure).
  • Its ubiquitous presence suggests that it poses no significant threat of malignant transformation, raising doubts about its relevance in melanoma development and its suitability as a target of directed therapy in patients with melanoma.
  • [MeSH-major] Melanocytes / pathology. Mutation. Nevus / genetics. Proto-Oncogene Proteins B-raf / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Anus Neoplasms / genetics. Anus Neoplasms / pathology. Anus Neoplasms / surgery. Back / pathology. Child. DNA Mutational Analysis. DNA, Neoplasm / analysis. Extremities / pathology. Female. Head and Neck Neoplasms / genetics. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / surgery. Humans. Male. Microdissection. Middle Aged. Urogenital Neoplasms / genetics. Urogenital Neoplasms / pathology. Urogenital Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18032947.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


13. Downs NJ, Schouten PW, Parisi AV, Turner J: Measurements of the upper body ultraviolet exposure to golfers: non-melanoma skin cancer risk, and the potential benefits of exposure to sunlight. Photodermatol Photoimmunol Photomed; 2009 Dec;25(6):317-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurements of the upper body ultraviolet exposure to golfers: non-melanoma skin cancer risk, and the potential benefits of exposure to sunlight.
  • The risk of developing a skin cancer or an eye disease as a result of incidental exposure to naturally occurring ultraviolet radiation in the outdoor environment is proportionately high in a Queensland population compared with fair-skinned population groups residing in comparable Northern Hemisphere latitudes.
  • METHODS: The erythemal and vitamin D effective ultraviolet exposure measured to the forearm, upper back and vertex are presented for individuals playing golf under various atmospheric conditions in a 7-month period extending from summer to winter.
  • RESULTS: Mean summertime exposures were measured in the 2008 study period as be 1.4, 2.2 and 3.2 standard erythema doses (SED) at forearm, upper back and vertex sites, respectively, compared with respective wintertime forearm, upper back and vertex exposures of 0.2, 0.3 and 0.5 SED, where summertime exposures were recorded in the mean solar zenith angle (SZA) ranges of 56-59 degrees and wintertime exposures were recorded in the mean SZA range 74-83 degrees.
  • Vitamin D(3) effective exposures were determined to vary from between 225, 325 and 475 J/m(2) during summer and 48, 59 and 88 J/m(2) during winter for the respective forearm, upper back and vertex body sites measured in the above mean SZA ranges.
  • [MeSH-major] Golf. Neoplasms, Radiation-Induced / epidemiology. Skin Neoplasms / etiology. Sunlight

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19906167.001).
  • [ISSN] 1600-0781
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  •  go-up   go-down


14. Clark LN, Shin DB, Troxel AB, Khan S, Sober AJ, Ming ME: Association between the anatomic distribution of melanoma and sex. J Am Acad Dermatol; 2007 May;56(5):768-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between the anatomic distribution of melanoma and sex.
  • BACKGROUND: Anatomic distribution of melanoma, thought to be different between men and women, has not been studied in the United States since the 1970s, although lifestyle and clothing habits have changed since then.
  • OBJECTIVE: To determine whether the anatomic distribution of melanoma varied between men and women at our institution in 2004 and in the 1970s, and to assess whether the anatomic distribution has changed over time.
  • RESULTS: For the 2004 patients, males had an increased relative risk compared to females of developing a melanoma on their head and neck (relative risk ratio [RRR] = 3.33; P = .01).
  • For the 1970s patients, this difference was not found, but males in the 1970s had higher odds of developing melanoma on their upper back, chest, and abdomen, while females in the 1970s had higher odds of developing melanoma on the upper extremity and lower extremity, particularly the lower legs and feet.
  • Examining differences over time, we found that women in 2004 had a decreased relative risk of developing a melanoma on the lower extremities as opposed to the trunk as compared to the 1970s (RRR = 0.42; P < .01).
  • We also found that women had increased odds of developing a melanoma on the chest in 2004 compared to the 1970s (OR = 2.65; P = .04), while men had increased odds of developing a melanoma on their lower legs in 2004 compared to the 1970s (OR = 3.18; P = .02).
  • LIMITATIONS: The study was performed at a single academic center and the results may not generalize to all melanoma populations.
  • CONCLUSIONS: There were significant differences between men and women in the anatomic distribution of melanoma in 2004 patients and in 1970s patients, but the nature of those differences changed over time.
  • [MeSH-major] Melanoma / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337091.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Krizkova S, Fabrik I, Adam V, Kukacka J, Prusa R, Chavis GJ, Trnkova L, Strnadel J, Horak V, Kizek R: Utilizing of Adsorptive Transfer Stripping Technique Brdicka Reaction for Determination of Metallothioneins Level in Melanoma Cells, Blood Serum and Tissues. Sensors (Basel); 2008 May 10;8(5):3106-3122
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utilizing of Adsorptive Transfer Stripping Technique Brdicka Reaction for Determination of Metallothioneins Level in Melanoma Cells, Blood Serum and Tissues.
  • In the paper we utilized the adsorptive transfer stripping differential pulse voltammetry Brdicka reaction for the determination of metallothioneins (MT) in melanoma cells, animal melanoma tissues (MeLiM miniature pig) and blood serum of patients with malignant melanoma.
  • Then we quantified the MT level in the melanoma cells, the animal melanoma tissues and the blood serum samples.
  • At animal melanoma tissues (melanomas localized on abdomen, back limb and dorsum) the highest content of MT was determined in the tumour sampled on the back of the animal and was nearly 500 μg of MTs per gram of a tissue.
  • Moreover the average MT level in the blood serum samples from patients with melanoma was 3.0 ± 0.8 μM.
  • MT levels determined at melanoma samples were significantly (p < 0.05) higher compared to control ones at cells, tissues and blood serum.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cancer Res Clin Oncol. 1996;122(6):351-5 [8642045.001]
  • [Cites] Int J Cancer. 2004 May 20;110(1):39-50 [15054867.001]
  • [Cites] Int J Cancer. 2003 Feb 20;103(5):631-5 [12494470.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):835-41 [16508630.001]
  • [Cites] J Am Acad Dermatol. 1982 Apr;6(4 Pt 1):540-3 [7076909.001]
  • [Cites] Neuro Endocrinol Lett. 2006 Dec;27 Suppl 2:116-20 [17159794.001]
  • [Cites] Arch Dermatol Res. 2001 Mar;293(3):115-20 [11357224.001]
  • [Cites] Anal Chem. 2001 Oct 15;73(20):4801-7 [11681454.001]
  • [Cites] Int J Cancer. 2000 Sep 15;87(6):809-11 [10956390.001]
  • [Cites] Talanta. 1998 Jun;46(2):271-89 [18967150.001]
  • [Cites] Melanoma Res. 2006 Feb;16(1):3-10 [16432450.001]
  • [Cites] Physiol Rev. 1985 Apr;65(2):238-309 [3885271.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2000 Mar;46(2):257-67 [10774918.001]
  • [Cites] Neuro Endocrinol Lett. 2005 Dec;26(6):663-6 [16380693.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1999 Nov;45(7):1119-29 [10644016.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2000 Mar;46(2):269-81 [10774919.001]
  • [Cites] World J Surg Oncol. 2005 Jan 17;3(1):5 [15655072.001]
  • [Cites] Analyst. 1998 Oct;123(10):2125-30 [10209897.001]
  • [Cites] Histopathology. 1993 Sep;23(3):257-63 [8225244.001]
  • [Cites] Talanta. 2002 Jul 19;57(6):1211-8 [18968728.001]
  • [Cites] Protein J. 2006 Jan;25(1):23-32 [16721658.001]
  • [Cites] Melanoma Res. 2003 Dec;13(6):543-8 [14646615.001]
  • [Cites] Histopathology. 1998 Aug;33(2):154-7 [9762548.001]
  • [Cites] Biochim Biophys Acta. 2000 Dec 15;1524(2-3):196-202 [11113568.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):653-4 [12424065.001]
  • [Cites] Neuro Endocrinol Lett. 2005 Oct;26(5):567-74 [16264399.001]
  • [Cites] Neoplasma. 2002;49(3):159-66 [12098001.001]
  • [Cites] Nat Genet. 1995 Jul;10(3):351-3 [7670475.001]
  • [Cites] J Inorg Biochem. 2002 Jan 15;88(2):123-34 [11803033.001]
  • [Cites] Pathol Oncol Res. 2004;10(2):74-9 [15188022.001]
  • [Cites] Oral Oncol. 2007 Mar;43(3):252-6 [16857408.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Dec;17(4):483-9 [10089072.001]
  • [Cites] Ann Hematol. 1994 Sep;69(3):111-5 [8086505.001]
  • [Cites] Talanta. 2006 Jul 15;69(5):1162-5 [18970698.001]
  • [Cites] Am J Dermatopathol. 2001 Feb;23(1):29-35 [11176049.001]
  • [Cites] J Med Genet. 2007 Feb;44(2):99-106 [16905682.001]
  • [Cites] Pigment Cell Res. 2004 Feb;17(1):24-35 [14717842.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2581-3 [15102657.001]
  • [Cites] Virchows Arch. 2005 Sep;447(3):626-33 [15968547.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Dec;10(4):357-62 [12607605.001]
  • [Cites] Bioelectrochemistry. 2003 Aug;60(1-2):29-36 [12893307.001]
  • [Cites] J Chromatogr A. 1998 Dec 31;829(1-2):127-36 [9923079.001]
  • [Cites] Histol Histopathol. 2007 Jul;22(7):719-28 [17455146.001]
  • [Cites] Appl Spectrosc. 2003 Mar;57(3):102A-112A [14658613.001]
  • [Cites] Br J Dermatol. 2003 Sep;149(3):535-41 [14510986.001]
  • [Cites] Neuro Endocrinol Lett. 2001 Dec;22(6):413-6 [11781537.001]
  • [Cites] Annu Rev Biochem. 1986;55:913-51 [3527054.001]
  • [Cites] Environ Sci Technol. 2003 Dec 15;37(24):5609-16 [14717171.001]
  • [Cites] Analyst. 2000 May;125(5):963-88 [10885060.001]
  • [Cites] Bioelectrochemistry. 2002 May 15;56(1-2):57-61 [12009444.001]
  • [Cites] Bioinorg Chem Appl. 2005;:43-53 [18365088.001]
  • [Cites] Anal Chem. 1998 Jul 1;70(13):2536-43 [9666725.001]
  • [Cites] Histopathology. 2004 Aug;45(2):103-18 [15279628.001]
  • [Cites] Biochemistry. 1988 Nov 15;27(23):8509-15 [3064814.001]
  • [Cites] Methods Enzymol. 1991;205:613-26 [1779825.001]
  • (PMID = 27879868.001).
  • [ISSN] 1424-8220
  • [Journal-full-title] Sensors (Basel, Switzerland)
  • [ISO-abbreviation] Sensors (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Adsorptive Transfer Stripping Technique / Animal Tissue / Brdicka Reaction / Cell / Differential Pulse Voltammetry / Human blood serum / Metallothionein / Protein / Tumour Marker
  •  go-up   go-down


16. English DR, Milne E, Simpson JA: Sun protection and the development of melanocytic nevi in children. Cancer Epidemiol Biomarkers Prev; 2005 Dec;14(12):2873-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Childhood sun exposure causes nevi (and melanoma), but there is little evidence regarding the effectiveness of sun protection strategies on the number of nevi.
  • The outcome was number of nevi on the back 6 years after baseline, when the children were 12 years old.
  • Using sunscreen on the back when it was uncovered was not associated with number of nevi (P = 0.59).
  • [MeSH-major] Nevus, Pigmented / prevention & control. Protective Clothing. Skin Neoplasms / prevention & control. Sunlight / adverse effects. Sunscreening Agents
  • [MeSH-minor] Back. Child. Dose-Response Relationship, Radiation. Female. Humans. Male. Surveys and Questionnaires. Western Australia / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Sun Exposure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16365003.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sunscreening Agents
  •  go-up   go-down


17. Uren RF, Howman-Giles R, Chung DK, Morton RL, Thompson JF: The reproducibility in routine clinical practice of sentinel lymph node identification by pre-operative lymphoscintigraphy in patients with cutaneous melanoma. Ann Surg Oncol; 2007 Feb;14(2):899-905
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The reproducibility in routine clinical practice of sentinel lymph node identification by pre-operative lymphoscintigraphy in patients with cutaneous melanoma.
  • Pre-operative lymphoscintigraphy (LS) is an important part of successful sentinel lymph node (SLN) biopsy in most melanoma treatment centers.
  • The test accurately maps lymphatic drainage from cutaneous melanoma sites and has been shown to be reproducible in prospective studies.
  • This has happened on 21 occasions at the Sydney Melanoma Unit and we have performed a retrospective analysis of the reproducibility of the LS results.
  • One showed two extra interval nodes on the back as well as concordant flow to SLNs in each axilla.
  • The other with a leg melanoma showed the same groin SLNs but failed to relabel the two popliteal SLNs on the second study.
  • These results indicate that in routine clinical practice LS is a highly reproducible procedure to locate and radiolabel the SLNs prior to biopsy in patients with melanoma.
  • [MeSH-major] Lymph Nodes / radionuclide imaging. Melanoma / radionuclide imaging. Sentinel Lymph Node Biopsy. Skin Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17103064.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid
  •  go-up   go-down


18. Kimlin MG, Martinez N, Green AC, Whiteman DC: Anatomical distribution of solar ultraviolet exposures among cyclists. J Photochem Photobiol B; 2006 Oct 2;85(1):23-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure to solar ultraviolet (UV) radiation is the major environmental factor implicated in the development of melanoma and other skin cancers, as well as eye damage and skin photoaging.
  • Mean doses received at the ankle (0.94 MED), back of the hand (1.28 MED) and side of the head (1.14 MED) were 51%, 71% and 63% of those received at the top of the head (1.80 MED), respectively.
  • [MeSH-major] Bicycling. Body Constitution / radiation effects. Neoplasms, Radiation-Induced / pathology. Skin / radiation effects. Skin Neoplasms / pathology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16730999.001).
  • [ISSN] 1011-1344
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


19. Busam KJ, Ariyan C, Coit DC: Desmoplastic melanoma in African American patients. Arch Dermatol; 2010 Jul;146(7):796-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic melanoma in African American patients.
  • [MeSH-major] African Americans. Melanoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Back. Biopsy. Cheek. Diagnosis, Differential. Female. Follow-Up Studies. Forearm. Humans


20. Hennessy SA, Dengel LT, Hranjec T, Slingluff CL Jr: A triangular intermuscular space sentinel node in melanoma: association with axillary lymphatic drainage. Ann Surg Oncol; 2010 Sep;17(9):2465-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A triangular intermuscular space sentinel node in melanoma: association with axillary lymphatic drainage.
  • BACKGROUND: Large centers have described triangular intermuscular space (TIS) sentinel nodes (SNs) for some melanomas of the back.
  • Among 293 patients with upper back melanoma, data were collected on those with TIS SN.
  • RESULTS: Fourteen patients (5%) with melanoma of the upper back had a TIS SN, 6 of whom (43%) were incorrectly identified at lymphoscintigraphy as axillary, and 11 of whom (79%) had a concurrent axillary SN.
  • We recommend directed evaluation for TIS SN in patients with upper back melanomas and recommend clearing the TIS at the time of TIS SN biopsy.
  • Melanoma can metastasize to TIS SN, and we discuss considerations for management of the axilla in patients with positive TIS nodes.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2001 Feb;88(2):305-8 [11167886.001]
  • [Cites] J Nucl Med. 2003 Apr;44(4):570-82 [12679402.001]
  • [Cites] Ann Surg Oncol. 2004 Mar;11(3 Suppl):179S-85S [15023748.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):120-30 [8129482.001]
  • [Cites] J Nucl Med. 1996 Jun;37(6):964-6 [8683322.001]
  • [Cites] J Am Coll Surg. 1999 Aug;189(2):195-204 [10437842.001]
  • [Cites] Lancet Oncol. 2005 Nov;6(11):877-85 [16257796.001]
  • [Cites] Ann Plast Surg. 2010 Jan;64(1):52-4 [20023455.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):811 [10622512.001]
  • [Cites] Arch Surg. 2000 Oct;135(10):1168-72 [11030873.001]
  • (PMID = 20221903.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI078875-01A1; United States / NIAID NIH HHS / AI / T32 AI078875; United States / NIAID NIH HHS / AI / T32 AI078875-02; United States / NIAID NIH HHS / AI / T32 AI078875-01A1
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS268192; NLM/ PMC3033783
  •  go-up   go-down


21. Hershkovitz L, Schachter J, Treves AJ, Besser MJ: Focus on adoptive T cell transfer trials in melanoma. Clin Dev Immunol; 2010;2010:260267
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focus on adoptive T cell transfer trials in melanoma.
  • Adoptive Cell Transfer (ACT) of Tumor-Infiltrating Lymphocytes (TIL) in combination with lymphodepletion has proven to be an effective treatment for metastatic melanoma patients, with an objective response rate in 50%-70% of the patients.
  • It is based on the ex vivo expansion and activation of tumor-specific T lymphocytes extracted from the tumor and their administration back to the patient.
  • [MeSH-major] Immunotherapy, Adoptive / methods. Lymphocytes, Tumor-Infiltrating / transplantation. Melanoma / therapy. T-Lymphocytes / transplantation

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1984 Sep 28;225(4669):1487-9 [6332379.001]
  • [Cites] N Engl J Med. 1985 Dec 5;313(23):1485-92 [3903508.001]
  • [Cites] JAMA. 1986 Dec 12;256(22):3117-24 [3491225.001]
  • [Cites] J Immunol Methods. 1987 Aug 3;101(2):171-81 [3611795.001]
  • [Cites] J Immunol Methods. 1987 Dec 24;105(2):183-92 [3693906.001]
  • [Cites] N Engl J Med. 1988 Dec 22;319(25):1676-80 [3264384.001]
  • [Cites] J Immunol. 1989 May 1;142(9):3329-35 [2785141.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Dec;86(24):10024-8 [2513569.001]
  • [Cites] N Engl J Med. 1990 Aug 30;323(9):570-8 [2381442.001]
  • [Cites] J Immunol. 1991 May 15;146(10):3674-81 [1902860.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 3;83(13):932-7 [2067036.001]
  • [Cites] J Immunother (1991). 1991 Jun;10(3):153-64 [1868040.001]
  • [Cites] J Immunol. 1992 Jan 15;148(2):638-43 [1729379.001]
  • [Cites] J Immunother (1991). 1992 Jul;12(1):1-12 [1637779.001]
  • [Cites] Immunity. 2005 Apr;22(4):403-14 [15845446.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1616-26 [15931392.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):7853-8 [15944290.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6 [15980149.001]
  • [Cites] J Exp Med. 2005 Oct 3;202(7):907-12 [16203864.001]
  • [Cites] J Clin Oncol. 2009 Dec 1;27(34):5763-71 [19884534.001]
  • [Cites] Cancer Immunol Immunother. 2010 Jun;59(6):921-31 [20101507.001]
  • [Cites] Mol Ther. 2010 Apr;18(4):843-51 [20179677.001]
  • [Cites] Clin Cancer Res. 2010 May 1;16(9):2646-55 [20406835.001]
  • [Cites] N Engl J Med. 2010 Aug 19;363(8):711-23 [20525992.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4 [8421711.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1993 Jan;13(1):18-30 [8435428.001]
  • [Cites] J Natl Cancer Inst. 1993 Apr 21;85(8):622-32 [8468720.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1475-83 [8021739.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66 [8028037.001]
  • [Cites] J Exp Med. 1997 Mar 3;185(5):833-41 [9120389.001]
  • [Cites] Immunity. 1998 May;8(5):615-23 [9620682.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):307-19 [9742914.001]
  • [Cites] J Immunol. 1998 Nov 15;161(10):5133-7 [9820481.001]
  • [Cites] J Immunol. 2004 Dec 15;173(12):7125-30 [15585832.001]
  • [Cites] Blood. 2005 Jan 1;105(1):241-50 [15345595.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2591-601 [15728465.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2346-57 [15800326.001]
  • [Cites] J Immunother. 2005 May-Jun;28(3):258-67 [15838383.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer J Sci Am. 2000 Feb;6 Suppl 1:S11-4 [10685652.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Mar;19(1):21-34 [10840932.001]
  • [Cites] Neoplasia. 2000 Sep-Oct;2(5):449-59 [11191112.001]
  • [Cites] Nature. 2001 May 17;411(6835):380-4 [11357146.001]
  • [Cites] J Immunol. 2001 Jul 15;167(2):1090-6 [11441120.001]
  • [Cites] Nat Biotechnol. 2002 Jan;20(1):70-5 [11753365.001]
  • [Cites] J Clin Invest. 2002 Jul;110(2):185-92 [12122110.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3155-63 [12384413.001]
  • [Cites] Science. 2002 Oct 25;298(5594):850-4 [12242449.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5):427-45 [12407508.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73 [12427970.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):35-45 [12509765.001]
  • [Cites] J Immunol. 2003 Jul 1;171(1):61-8 [12816983.001]
  • [Cites] J Immunother. 2003 Jul-Aug;26(4):332-42 [12843795.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3127-32 [12915604.001]
  • [Cites] Nat Med. 2004 Sep;10(9):909-15 [15340416.001]
  • [Cites] N Engl J Med. 2004 Sep 2;351(10):998-1012 [15342808.001]
  • [Cites] J Immunol. 2005 Nov 15;175(10):7046-52 [16272366.001]
  • [Cites] Dermatol Ther. 2006 Jan-Feb;19(1):19-25 [16405566.001]
  • [Cites] Isr Med Assoc J. 2006 Mar;8(3):164-8 [16599050.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):e20-2 [16648493.001]
  • [Cites] J Immunol. 2006 Jun 15;176(12):7726-35 [16751420.001]
  • [Cites] Science. 2006 Oct 6;314(5796):126-9 [16946036.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15 [17062687.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Dec;3(12):668-81 [17139318.001]
  • [Cites] J Immunother. 2007 Jan;30(1):123-9 [17198091.001]
  • [Cites] J Clin Invest. 2007 Feb;117(2):492-501 [17273561.001]
  • [Cites] Semin Oncol. 2007 Dec;34(6):524-31 [18083376.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Immunol. 2008 May 1;180(9):6116-31 [18424733.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5326-33 [18276844.001]
  • [Cites] J Clin Oncol. 2008 Jul 10;26(20):3445-55 [18612161.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2261-71 [18509084.001]
  • [Cites] J Immunother. 2008 Oct;31(8):742-51 [18779745.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5233-9 [18809613.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):169-80 [19118044.001]
  • [Cites] Cancer J. 2009 Mar-Apr;15(2):150-4 [19390311.001]
  • [Cites] Mol Syst Biol. 2009;5:265 [19401677.001]
  • [Cites] J Immunother. 2009 May;32(4):415-23 [19342963.001]
  • [Cites] Curr Opin Immunol. 2009 Apr;21(2):215-23 [19327974.001]
  • [Cites] Hematol Oncol Clin North Am. 2009 Jun;23(3):583-97, x [19464604.001]
  • [Cites] Blood. 2009 Jul 16;114(3):535-46 [19451549.001]
  • [Cites] Clin Cancer Res. 2009 Sep 15;15(18):5852-60 [19737958.001]
  • [Cites] Hum Gene Ther. 2008 Nov;19(11):1219-32 [19848582.001]
  • (PMID = 21234353.001).
  • [ISSN] 1740-2530
  • [Journal-full-title] Clinical & developmental immunology
  • [ISO-abbreviation] Clin. Dev. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC3018069
  •  go-up   go-down


22. Aktürk AS, Bilen N, Bayrämgürler D, Demirsoy EO, Erdogan S, Kiran R: Dermoscopy is a suitable method for the observation of the pregnancy-related changes in melanocytic nevi. J Eur Acad Dermatol Venereol; 2007 Sep;21(8):1086-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main problem is that whether it is a usual finding, or it is a condition that requires suspicion about melanoma.
  • Of nevi whose diameters increased, 10 (50.00%) were localized on the front of body, 6 (30.00%) on the face and neck, 3 (15.00%) on the legs, and 1 (5.00%) on the back.
  • We also think that these findings might be connected with expansion of the skin during pregnancy.
  • [MeSH-major] Dermoscopy. Melanocytes / pathology. Nevus, Pigmented / pathology. Pregnancy Complications, Neoplastic / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17714130.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


23. Shellman YG, Ribble D, Miller L, Gendall J, Vanbuskirk K, Kelly D, Norris DA, Dellavalle RP: Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Res; 2005 Apr;15(2):83-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lovastatin-induced apoptosis in human melanoma cell lines.
  • The cholesterol-lowering medications, statins, inhibit cellular proliferation and induce apoptosis in an array of cancer cell lines, including melanoma.
  • We investigated the apoptotic mechanism of lovastatin on human melanoma cell lines in vitro.
  • Farnesyl pyrophosphate and geranylgeranyl pyrophosphate add-back experiments were performed to better define the molecular mechanisms mediating lovastatin cytotoxicity.
  • Lovastatin caused cytotoxicity in human and murine melanoma cells, but did not induce toxicity in an epidermoid carcinoma cell line A431.
  • For human melanoma cells, lovastatin precipitated cell rounding, increased the percentage of apoptotic cells detected by ethidium bromide and acridine orange staining and by the Annexin V apoptosis detection kit, and resulted in a 50-fold increase in active caspase 3, corroborating that lovastatin induced apoptosis.
  • Adding back geranylgeranyl pyrophosphate, but not farnesyl pyrophosphate, reversed the effects of lovastatin in A375 cells.
  • Of the five statins tested, pravastatin was least effective in killing melanoma cells.
  • Lovastatin induced caspase-dependent apoptosis in multiple melanoma cell lines via a geranylation-specific mechanism.
  • This study supports a possible role of lovastatin as a therapeutic, adjuvant or chemopreventive agent for melanoma.
  • [MeSH-major] Apoptosis / drug effects. Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology. Lovastatin / pharmacology. Melanoma / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Statins.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOVASTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15846140.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K-07 CA92550-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Polyisoprenyl Phosphates; 0 / Sesquiterpenes; 6699-20-3 / geranylgeranyl pyrophosphate; 79W6B01D07 / farnesyl pyrophosphate; 9LHU78OQFD / Lovastatin; EC 2.5.1.1 / Dimethylallyltranstransferase; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; KXO2KT9N0G / Pravastatin
  •  go-up   go-down


24. Koga M, Kai H, Egami K, Murohara T, Ikeda A, Yasuoka S, Egashira K, Matsuishi T, Kai M, Kataoka Y, Kuwano M, Imaizumi T: Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Commun; 2008 Jan 11;365(2):279-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice.
  • We investigated whether blocking of monocyte chemoattractant-1 (MCP-1) function would inhibit recruitment of tumor-associated macrophages (TAMs) and prevent tumor angiogenesis and tumor growth of human malignant melanoma.
  • B16-F1 melanoma cells were implanted onto the back of C57BL/6 mice (Day 0).
  • Melanoma cells expressed not only MCP-1 but also its receptor CCR2.
  • Accordingly, it was suggested that MCP-1 would enhance tumor angiogenesis and early tumor growth in the early stages by inducing TNFalpha, IL-1alpha, and VEGF through TAM recruitment and probably the direct autocrine/paracrine effects on melanoma cells.
  • [MeSH-major] Chemokine CCL2 / genetics. Genetic Therapy / methods. Melanoma / genetics. Melanoma / therapy. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / prevention & control

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991428.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCL2 protein, human; 0 / Chemokine CCL2
  •  go-up   go-down


25. Drugge RJ, Nguyen C, Drugge ED, Gliga L, Broderick PA, McClain SA, Brown CC: Melanoma screening with serial whole body photographic change detection using Melanoscan technology. Dermatol Online J; 2009;15(6):1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma screening with serial whole body photographic change detection using Melanoscan technology.
  • The use of an automated, whole-body, diffusely lit digital imaging enclosure to produce serial images, which were then compared, using an astrophysics image display method, enabled a private practice dermatologist to detect melanoma at significantly thinner Breslow depths compared to all other clinical detection paradigms examined in this study.
  • The patients were triaged to scanning using a melanoma risk survey system.
  • The system employed a 24 camera semicircular imaging wall, with front and back views.
  • Image to image comparison of whole body digital photography was combined with a whole body skin exam in order to sensitize a clinical dermatologist to skin changes in individuals at risk for melanoma.
  • Mean depths (Breslow scores) were compiled from six distinct melanoma biopsy cohorts segregated and based on different clinical screening paradigms.
  • This approach provides a quick and effective method for detection of early melanomas with a significant reduction in the skin area required for lesion examination.
  • [MeSH-major] Melanoma / pathology. Photography. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19723475.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Strik H, Prömmel P: [Neoplastic meningitis. Diagnosis and individualised therapy]. Nervenarzt; 2010 Feb;81(2):229-41; quiz 242
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoplastic meningitis. Diagnosis and individualised therapy].
  • It occurs in approximately 5-10% of malignant diseases, most often in breast cancer, lung cancer, melanoma, and B-cell lymphoma.
  • Symptoms of neoplastic meningitis include head or back pain, cranial nerve palsies, diffuse radicular symptoms, and psychiatric disturbances.
  • [MeSH-major] Meningeal Carcinomatosis / diagnosis. Meningeal Carcinomatosis / secondary. Meningitis, Aseptic / diagnosis

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20140544.001).
  • [ISSN] 1433-0407
  • [Journal-full-title] Der Nervenarzt
  • [ISO-abbreviation] Nervenarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 53
  •  go-up   go-down


27. Geller AC, Johnson TM, Miller DR, Brooks KR, Layton CJ, Swetter SM: Factors associated with physician discovery of early melanoma in middle-aged and older men. Arch Dermatol; 2009 Apr;145(4):409-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with physician discovery of early melanoma in middle-aged and older men.
  • OBJECTIVE: To determine factors associated with physician discovery of early melanoma in middle-aged and older men.
  • SETTING: Three institutional melanoma clinics.
  • PARTICIPANTS: A total of 227 male participants (aged > or =40 years) with invasive melanoma who completed surveys within 3 months of diagnosis.
  • MAIN OUTCOME MEASURES: Factors associated with physician-detected thin melanoma.
  • RESULTS: Patients with physician-detected melanoma were older, 57% were 65 years or older compared with 34% for other-detected (odds ratio [OR], 2.57; 95% confidence interval [CI], 1.19-5.55) and 42% for patient-detected melanoma (P = .07).
  • Physician-detected melanoma in the oldest patients (aged > or =65 years) had tumor thickness equal to that of self-detected melanoma or melanoma detected by other means in younger patients.
  • Back lesions composed 46% of all physician-detected melanoma, 57% of those detected by other means, and 16% of self-detected lesions (physician- vs self-detected: OR, 4.25; 95% CI, 1.96-9.23).
  • Ninety-two percent of all physician-detected back-of-the-body melanomas were smaller than 2 mm compared with 63% of self-detected lesions (P = .004) and 76% of lesions detected by other means (P = .07).
  • CONCLUSIONS: Skin screenings of at-risk middle-aged and older American men can be integrated into the routine physical examination, with particular emphasis on hard-to-see areas, such as the back of the body.
  • "Watch your back" professional education campaigns should be promoted by skin cancer advocacy organizations.
  • [MeSH-major] Melanoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Dermatology. Early Diagnosis. Humans. Male. Middle Aged. Patient Education as Topic. Physicians. Self Care

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JAMA. 2009 Apr 22;301(16):1702-4 [19388140.001]
  • (PMID = 19380662.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Lanteri G, Marino F, Laganà G, Bellocco E, Barreca D, Liotta L, Sfacteria A, Macrì B: Acquired melanosis caused by acorn ingestion in the Nero Siciliano pig. Vet Pathol; 2009 Mar;46(2):329-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanosis of fat was observed in 2 animals and was limited to the back.
  • Stains for human melanoma, as well as S-100 protein, did not show any reaction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19261647.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Gerszten PC, Germanwala A, Burton SA, Welch WC, Ozhasoglu C, Vogel WJ: Combination kyphoplasty and spinal radiosurgery: a new treatment paradigm for pathological fractures. Neurosurg Focus; 2005 Mar 15;18(3):e8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Patients with symptomatic pathological compression fractures require a stabilization procedure for mechanical control of back pain as well as radiation therapy for the underlying malignant process.
  • Histological findings included 11 lung, nine breast, and four renal carcinomas, one cholangiocarcinoma, and one ocular melanoma.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771398.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Braun-Falco M: Combined malignant melanoma and basal cell carcinoma tumor of the intermingled type. J Cutan Pathol; 2007 Sep;34(9):731-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined malignant melanoma and basal cell carcinoma tumor of the intermingled type.
  • BACKGROUND: The combination of malignant melanoma (MM) and basal cell carcinoma (BCC) within a single tumor is an unusual finding.
  • CASE REPORT: An 84-year-old white man with a pigmented tumor on the back showing a combination of MM and BCC.
  • RESULTS: A 1.5 x 1.5-cm irregular brown lesion on the back was clinically suggestive of MM.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696923.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


31. Reguiaï Z, Jovenin N, Bernard P, Derancourt C: Melanoma, past severe sunburns and multiple solar lentigines of the upper back and shoulders. Dermatology; 2008;216(4):330-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma, past severe sunburns and multiple solar lentigines of the upper back and shoulders.
  • BACKGROUND: Multiple solar lentigines of the upper back and shoulders (MSLBS) have recently been demonstrated as being associated with intense sunburns in the past.
  • OBJECTIVE: To determine the prevalence of MSLBS among patients with cutaneous melanoma.
  • One hundred and twenty-five adult patients, followed up for a cutaneous melanoma, were included, and the prevalence of MSLBS was determined, with comparison of clinical characteristics of patients with and without these lesions.
  • RESULTS: The prevalence of MSLBS among patients with cutaneous melanoma was 37.6%.
  • MSLBS were significantly and independently associated with cutaneous melanoma of the back in multivariate analysis (adjusted odds ratio, OR = 4.3, 95% confidence interval, CI = 1.5-12.3) and with recalled episodes of severe sunburn before the age of 28 (OR = 3.4, 95% CI = 1.3-9.4).
  • CONCLUSION: Large irregularly shaped brown macules of the upper back and shoulders or MSLBS are frequent among adult patients with cutaneous melanoma.
  • They are associated with melanoma located on the upper back.
  • This topographical association further illustrates the relation between past intense sunburns and cutaneous melanoma.
  • MSLBS should be evaluated as an easily recognizable clinical marker of the risk of cutaneous melanoma.
  • [MeSH-major] Lentigo / epidemiology. Skin Neoplasms / epidemiology. Sunburn / complications. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Aged. Back. Female. Humans. Male. Melanoma / epidemiology. Melanoma / etiology. Middle Aged. Odds Ratio. Prevalence. Prospective Studies. Risk Factors. Skin Pigmentation

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Sun Exposure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18230982.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


32. Eichhoff OM, Zipser MC, Xu M, Weeraratna AT, Mihic D, Dummer R, Hoek KS: The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report. Melanoma Res; 2010 Aug;20(4):349-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report.
  • To date there is no effective therapy for metastatic melanoma and at the molecular level the disease progression is poorly understood.
  • A recent study by our group led to the development of a novel phenotype switching model for melanoma progression, wherein cells transition back-and-forth between states of proliferation and invasion to drive disease progression.
  • To explore the model's clinical relevance we interrogated phenotype-specific expression patterns in human melanoma patient material.
  • A matched primary/metastasis pair from a human melanoma patient was obtained and immunohistochemically stained for proliferative and invasive phenotype markers.
  • Strikingly, we observed that late phase metastatic melanoma cells adopt morphologies and behaviours identical to very early phase cells.
  • These results highlight the likelihood that disease progression involves melanoma cells retaining the capacity to regulate the expression of metastatic potential critical factors according to changing microenvironmental conditions.
  • [MeSH-major] Melanoma / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Aug 3;406(6795):536-40 [10952317.001]
  • [Cites] PLoS Genet. 2009 Mar;5(3):e1000427 [19300477.001]
  • [Cites] Am J Pathol. 2003 Jul;163(1):333-43 [12819038.001]
  • [Cites] Histopathology. 2004 Jun;44(6):517-41 [15186267.001]
  • [Cites] Histochemistry. 1981;72(3):433-42 [7298384.001]
  • [Cites] J Clin Pathol. 1990 Sep;43(9):752-7 [2212067.001]
  • [Cites] J Clin Pathol. 1992 Feb;45(2):143-8 [1371777.001]
  • [Cites] Connect Tissue Res. 1993;29(3):171-80 [8222644.001]
  • [Cites] Trends Genet. 1997 Apr;13(4):157-62 [9097727.001]
  • [Cites] Blood. 1997 Apr 15;89(8):2999-3008 [9108421.001]
  • [Cites] Annu Rev Genet. 2004;38:365-411 [15568981.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):51-65 [16822996.001]
  • [Cites] Pigment Cell Res. 2006 Aug;19(4):290-302 [16827748.001]
  • [Cites] World J Gastroenterol. 2006 Jul 14;12(26):4259-61 [16830389.001]
  • [Cites] Genes Dev. 2006 Dec 15;20(24):3426-39 [17182868.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):246-55 [17384580.001]
  • [Cites] Chemotherapy. 2007;53(4):233-56 [17595539.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):650-6 [18245463.001]
  • [Cites] Pigment Cell Melanoma Res. 2008 Dec;21(6):665-76 [19067971.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10205-14 [19074888.001]
  • [Cites] Dev Biol. 2009 Feb 15;326(2):285-94 [19100728.001]
  • [Cites] Traffic. 2002 Sep;3(9):678-93 [12191019.001]
  • (PMID = 20526217.001).
  • [ISSN] 1473-5636
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA AG000449-02
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MITF protein, human; 0 / MLANA protein, human; 0 / Microphthalmia-Associated Transcription Factor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS212573; NLM/ PMC2901773
  •  go-up   go-down


33. Vassallo C, Muzio F, Brazzelli V, Ester O, Lazzarino M, Borroni G: Primary dermal melanoma occurring in a patient affected by Philadelphia-positive chronic myeloid leukaemia. J Eur Acad Dermatol Venereol; 2007 Oct;21(9):1300-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary dermal melanoma occurring in a patient affected by Philadelphia-positive chronic myeloid leukaemia.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Back. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17894751.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


34. Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N: Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des; 2008;14(11):1049-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors which usually do not express ASS include melanoma, hepatocellular carcinoma, some mesotheliomas and some renal cell cancers.
  • Citrulline can be recycled back to arginine in normal cells which express ASS, whereas ASS(-) tumor cells cannot.
  • A pegylated form of ADI (ADI-PEG20) has been formulated and has shown in vitro and in vivo activity against melanoma and hepatocellular carcinoma.
  • ADI-PEG20 induces apoptosis in melanoma cell lines.
  • However, arginine deprivation can also induce ASS expression in certain melanoma cell lines which can lead to in vitro drug resistance.
  • Phase I and II clinical trials with ADI-PEG20 have been conducted in patients with melanoma and hepatocellular carcinoma, and antitumor activity has been demonstrated in both cancers.

  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1982 May 10;257(9):5061-7 [6279658.001]
  • [Cites] Biochem J. 1983 Nov 15;216(2):281-5 [6661196.001]
  • [Cites] J Biochem. 1985 Nov;98(5):1395-403 [4086486.001]
  • [Cites] Arch Biochem Biophys. 1987 Jul;256(1):343-53 [3038025.001]
  • [Cites] Mol Endocrinol. 1988 May;2(5):444-51 [2843756.001]
  • [Cites] J Biol Chem. 1988 Nov 5;263(31):16388-94 [3182797.001]
  • [Cites] Cancer Res. 1990 Jan 15;50(2):345-9 [2403840.001]
  • [Cites] Mol Cell Biol. 1991 Apr;11(4):1935-43 [2005889.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):2932-9 [1903327.001]
  • [Cites] Int J Cancer. 1992 May 8;51(2):244-9 [1568792.001]
  • [Cites] Melanoma Res. 1992 Sep;2(3):191-6 [1450673.001]
  • [Cites] Arch Biochem Biophys. 1993 Mar;301(2):237-43 [8460937.001]
  • [Cites] Jpn J Cancer Res. 1993 Nov;84(11):1195-200 [8276724.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Oct 4;215(1):148-53 [7575582.001]
  • [Cites] Jpn J Cancer Res. 1995 Sep;86(9):840-6 [7591961.001]
  • [Cites] FEBS Lett. 1996 Dec 16;399(3):310-2 [8985169.001]
  • [Cites] Hepatology. 1997 Apr;25(4):964-9 [9096605.001]
  • [Cites] Am J Physiol. 1998 Jul;275(1 Pt 1):E79-86 [9688877.001]
  • [Cites] Crit Rev Oncol Hematol. 1998 Aug;28(2):97-113 [9768345.001]
  • [Cites] Biochem J. 1998 Nov 15;336 ( Pt 1):1-17 [9806879.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jul 22;261(1):10-4 [10405315.001]
  • [Cites] Adv Exp Med Biol. 1999;457:621-9 [10500842.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):18717-27 [15772076.001]
  • [Cites] Semin Cancer Biol. 2005 Aug;15(4):247-53 [15886013.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14238-43 [16176982.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7660-8 [16234528.001]
  • [Cites] Curr Opin Cell Biol. 2005 Dec;17(6):596-603 [16226444.001]
  • [Cites] Cancer Lett. 2006 Jan 8;231(1):30-5 [16356828.001]
  • [Cites] Am J Clin Nutr. 2006 Feb;83(2):508S-512S [16470022.001]
  • [Cites] Curr Opin Mol Ther. 2006 Jun;8(3):240-8 [16774044.001]
  • [Cites] Postepy Hig Med Dosw (Online). 2006;60:483-9 [17013367.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7126-31 [17145837.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):897-905 [17096330.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Jan;22(1):86-91 [17201887.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):309-17 [17210712.001]
  • [Cites] Proteomics. 2007 Feb;7(4):565-77 [17309102.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):573-6 [12888832.001]
  • [Cites] Leukemia. 2000 May;14(5):826-9 [10803513.001]
  • [Cites] Mol Cells. 2000 Jun 30;10(3):331-7 [10901172.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):800-10 [10952786.001]
  • [Cites] Brain Res Mol Brain Res. 2000 Nov 10;83(1-2):1-8 [11072090.001]
  • [Cites] J Control Release. 2002 Apr 23;80(1-3):259-71 [11943403.001]
  • [Cites] Cancer Lett. 2002 Sep 26;183(2):155-62 [12065090.001]
  • [Cites] Med Sci Monit. 2002 Jul;8(7):BR248-53 [12118186.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5443-50 [12359751.001]
  • [Cites] Genes Cells. 2003 Jan;8(1):65-79 [12558800.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):613-23 [12592378.001]
  • [Cites] Cancer Lett. 2003 Mar 10;191(2):165-70 [12618329.001]
  • [Cites] Mol Cell Biochem. 2003 Feb;244(1-2):177-85 [12701828.001]
  • [Cites] Eur J Biochem. 2003 May;270(9):1887-99 [12709047.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):723-8 [12866032.001]
  • [Cites] Br J Cancer. 2003 Sep 1;89(5):907-14 [12942125.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1214-6 [14571701.001]
  • [Cites] Biochem Pharmacol. 2003 Nov 15;66(10):1945-52 [14599552.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 9;313(2):443-6 [14684182.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52504-10 [14570901.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):826-33 [14770441.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1815-22 [15143074.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36192-200 [15192091.001]
  • [Cites] Clin Sci (Lond). 2004 Oct;107(4):371-9 [15157183.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):502-8 [15382078.001]
  • [Cites] Anticancer Drugs. 2004 Oct;15(9):825-33 [15457122.001]
  • [Cites] J Nutr. 2004 Oct;134(10 Suppl):2837S-2841S; discussion 2853S [15465796.001]
  • [Cites] Br J Cancer. 1974 Jul;30(1):50-9 [4528778.001]
  • [Cites] Cytogenet Cell Genet. 1979;23(3):171-81 [219990.001]
  • [Cites] Br J Cancer. 1979 Jun;39(6):613-20 [444403.001]
  • [Cites] Eur J Biochem. 1979 Jun;97(1):29-35 [477671.001]
  • [Cites] J Biol Chem. 1981 Nov 25;256(22):11826-31 [6170638.001]
  • [Cites] J Biol Chem. 1982 Mar 10;257(5):2246-53 [7061421.001]
  • (PMID = 18473854.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109578-02; United States / NCI NIH HHS / CA / R01CA109578; United States / NCI NIH HHS / CA / CA109578-03; United States / NCI NIH HHS / CA / R01 CA109578; United States / NCI NIH HHS / CA / CA109578-01; United States / NCI NIH HHS / CA / CA109578-02; United States / NCI NIH HHS / CA / R01 CA109578-01; United States / NCI NIH HHS / CA / R01 CA109578-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 30IQX730WE / Polyethylene Glycols; 94ZLA3W45F / Arginine; EC 3.- / Hydrolases; EC 3.5.3.6 / ADI PEG20; EC 6.3.4.5 / Argininosuccinate Synthase
  • [Number-of-references] 75
  • [Other-IDs] NLM/ NIHMS287629; NLM/ PMC3096551
  •  go-up   go-down


35. Cho EA, Lee MA, Kang H, Lee SD, Kim HO, Park YM: Vitiligo-like Depigmentation Associated with Metastatic Melanoma of an Unknown Origin. Ann Dermatol; 2009 May;21(2):178-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitiligo-like Depigmentation Associated with Metastatic Melanoma of an Unknown Origin.
  • Although malignant melanoma usually occurs after the diagnosis of vitiligo-like depigmentation, the latter is rarely followed by the former.
  • We herein report on such a case in which recognition of the vitiligo-like depigmentation preceded diagnosing the metastatic melanoma by several months.
  • A 56-year-old woman had first developed vitiligo-like depigmentation on the forehead, eyelids, neck and back 18 months previously and thereafter she detected a hard mass in the left axilla 2 months previously.
  • Based on the histologic findings, the axillary mass was diagnosed as metastatic melanoma.
  • Our case suggests that the vitiligo-like depigmentation could be a sign that heralds metastatic melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2001 Dec;117(6):1464-70 [11886510.001]
  • [Cites] Cancer Immunol Immunother. 1996 Jun;42(5):263-7 [8706046.001]
  • [Cites] Ann Dermatol Venereol. 1978 Dec;105(12):1043-52 [753117.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Oct;20(9):1135-7 [16987274.001]
  • [Cites] J Am Acad Dermatol. 1983 Nov;9(5):696-708 [6643768.001]
  • [Cites] Arch Dermatol. 1995 Mar;131(3):314-8 [7887661.001]
  • [Cites] J Exp Med. 2000 Dec 4;192(11):1637-44 [11104805.001]
  • [Cites] Int J Dermatol. 2006 Aug;45(8):952-6 [16911383.001]
  • [Cites] J Cutan Pathol. 2008 May;35(5):433-44 [18399807.001]
  • [Cites] Clin Exp Dermatol. 1991 Jul;16(4):303-5 [1794178.001]
  • [Cites] Dermatologica. 1991;183(4):239-45 [1809584.001]
  • [Cites] Surgery. 1974 Apr;75(4):477-86 [4131002.001]
  • [Cites] J Am Acad Dermatol. 1983 Nov;9(5):689-96 [6643767.001]
  • [Cites] Pigment Cell Res. 1995 Feb;8(1):60-3 [7792256.001]
  • [Cites] Cancer Immunol Immunother. 1994 Jun;38(6):411-6 [8205563.001]
  • [Cites] Arch Dermatol. 1987 Aug;123(8):1053-5 [3631983.001]
  • (PMID = 20523781.001).
  • [ISSN] 2005-3894
  • [Journal-full-title] Annals of dermatology
  • [ISO-abbreviation] Ann Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2861199
  • [Keywords] NOTNLM ; Metastatic melanoma / Vitiligo-like depigmentation
  •  go-up   go-down


36. McGregor DH, Cherian R, Romanas MM, Ulusarac O, Mathur SC, Feldman MM: Amelanotic malignant melanoma: two collision tumors presenting as basal cell carcinoma and atypical fibroxanthoma. Ann Clin Lab Sci; 2008;38(2):157-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amelanotic malignant melanoma: two collision tumors presenting as basal cell carcinoma and atypical fibroxanthoma.
  • Collision (contiguous) tumors of the skin can result in misleading clinicopathological presentations, and the choice of appropriate diagnostic techniques may prevent incomplete diagnosis and management.
  • We report 2 cases of collision tumors involving amelanotic malignant melanoma of the back.
  • Subsequent excision showed that the lesion was largely composed of amelanotic melanoma underlying a relatively small and thin basal cell carcinoma, and this probably would have been demonstrated in a punch (rather than shave) biopsy.
  • The other patient is a 71-yr-old male with a 1 cm exophytic lesion on the back, which was determined microscopically to be melanoma, and a 0.6 cm papule on the back.
  • This lesion was composed of 2 distinct contiguous neoplastic infiltrates, the predominant component being an atypical fibroxanthoma and the smaller component an amelanotic melanoma (primary vs metastatic), with diagnostic confirmation requiring multiple immunohistochemical stains.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Histiocytoma, Benign Fibrous / diagnosis. Melanoma, Amelanotic / diagnosis. Neoplasms, Multiple Primary / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469362.001).
  • [ISSN] 1550-8080
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Ferrari A, Lozzi GP, Fargnoli MC, Peris K: Dermoscopic evolution of a congenital combined nevus in childhood. Dermatol Surg; 2005 Nov;31(11 Pt 1):1448-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermoscopically, combined nevus can mimic melanoma owing to the presence of dermoscopic features common to both types of lesions.
  • RESULTS: An asymptomatic plaque with a central blue area and peripheral brown pigmentation located on the back of a 13-year-old boy was diagnosed dermoscopically as combined nevus.
  • Surgical excision is recommended when clinical and dermoscopic features are equivocal and the diagnosis of melanoma cannot be ruled out.
  • [MeSH-major] Dermoscopy. Nevus, Blue / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Back. Diagnosis, Differential. Humans. Male. Melanoma / diagnosis

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16416618.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Herlyn M: Molecular targets in melanoma: strategies and challenges for diagnosis and therapy. Int J Cancer; 2006 Feb 1;118(3):523-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular targets in melanoma: strategies and challenges for diagnosis and therapy.
  • In coming years, we expect rapid advances in cutaneous melanoma diagnosis and therapy, because of the incorporation of new technologies into experimental and clinical research.
  • Major discoveries in melanoma are often made by investigators outside the field, and the melanoma research community will need to develop a better means of incorporating these advances into their work, to capitalize on the promise they hold for patients.
  • A far greater level of cooperation between labs and clinics will be to bring new technology-based discoveries from bench-to-bedside and back.
  • Metastatic melanoma should become a treatable disease in the next few years, because specific inhibitors are expected for most major targets.
  • [MeSH-major] Melanoma / diagnosis. Melanoma / therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16258898.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


39. Pizzichetta MA, Massone C, Soyer HP: Regression of atypical nevus: an anecdotal dermoscopic observation. Dermatol Surg; 2006 Oct;32(10):1274-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Clark nevi (atypical melanocytic nevi) can be considered as risk markers and potential precursors of melanoma.
  • CASE REPORT: A 43-year-old man had a brown macule on his back, sized 5 mm, with an irregular shape, clinically and dermoscopically diagnosed as an equivocal melanocytic lesion.
  • The histopathologic diagnosis was consistent with an atypical junctional nevus with regression with features of a Clark nevus.
  • [MeSH-major] Dermoscopy. Neoplasm Regression, Spontaneous / pathology. Nevus / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Back. Disease Progression. Follow-Up Studies. Humans. Male

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17034379.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. López Almaraz R, Villafruela Alvarez C, Rodríguez Luis J, Doménech Martínez E: [Neonatal neoplasms: a single-centre experience]. An Pediatr (Barc); 2006 Dec;65(6):529-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Neoplasias neonatales: experiencia de un centro.
  • INTRODUCTION: Malignant tumors are uncommon in the neonatal period and benign tumors may have malignant potential.
  • OBJECTIVES: To describe the neoplasms diagnosed and treated in newborns (</= 28 days of life) in the Hospital Universitario de Canarias and their association with congenital abnormalities and to evaluate prenatal diagnosis of these tumors.
  • The variables analyzed were the percentage of neonatal neoplasms among the total number of cancer cases in children aged less than 14 years, their incidence among all the newborns in our hospital, sex, year of diagnosis, age at clinical diagnosis, the presence or absence of prenatal diagnosis, type of tumor (histologic diagnosis), association with syndromes or other congenital anomalies, treatment, and long-term outcome.
  • Males accounted for 43.8 % and females for 56.2 %, with a mean age at diagnosis of 5.5 days (range 1-28 days).
  • Five neonates (31.2 %) had a prenatal diagnosis, 60 % of which were made in the last 7 years of the study period.
  • Histologic diagnoses were neuroblastoma (n = 5; 31.2 %), teratoma/ germ cell tumor (n = 4; 25 %), soft tissue sarcoma (one fibrosarcoma of the thigh and two hemangiopericytoma of the back and heart; 18.8 %), and one case each of mesoblastic nephroma, cerebral tumor (ependymoblastoma), melanoma (associated with giant congenital melanocytic nevi), and acute leukemia (associated with Down syndrome).
  • In the last 7 years, the prenatal diagnosis of these entities has improved.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] An Pediatr (Barc). 2007 Jul;67(1):85-6 [17663916.001]
  • (PMID = 17194321.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


41. Ingordo V, Gentile C, Iannazzone SS, Cusano F, Naldi L: Congenital melanocytic nevus: an epidemiologic study in Italy. Dermatology; 2007;214(3):227-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All the subjects examined from September 2002 to March 2004 showing skin lesions evocative of CMN were referred by general practitioners of the Draft's Council Medical Unit to the Department of Dermatology of the Italian Navy Hospital for confirming the diagnosis, which was based on the clinical features and the personal history.
  • Three CMN (1.9%) were located on the face, 23 (14.6%) on the chest, 24 (15.2%) on the abdomen, 36 (22.9%) on the back, 48 (30.5%) on the lumbar area, 15 (9.5%) on the upper limb, 19 (12.1%) on the lower limb and 15 (9.5%) on the shoulder.
  • None of the examined subjects reported a personal history of malignant melanoma (MM), and no person with a history of MM was observed among all the enlisted men referred to the Department of Dermatology during the time of the study.
  • [MeSH-major] Nevus, Pigmented / congenital. Nevus, Pigmented / epidemiology. Skin Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17377384.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


42. Mineo JF, P-Ruchoux MM, Pasquier D, Rigolle H, Assaker R: [Primitive malignant melanoma arising in a spinal nerve root. A case report]. Neurochirurgie; 2006 Jun;52(2-3 Pt 1):133-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primitive malignant melanoma arising in a spinal nerve root. A case report].
  • We report the fourth case of primitive malignant melanoma arising in a spinal nerve root.
  • A 39-year-old woman complained of one-year low back pain radiating to the right thigh and knee, and loss of 7 kg.
  • Due to the scalloping of L3/L4 foramen with root enlargement and slow evolution (more than one year between the first symptom and surgery without clinical worsening), the initial preoperative diagnosis was L3 schwannoma.
  • Immunohistochemistry showed melanin, HMB-45 and S100 positivity, but reticulin was negative (that eliminates malignant melanocytic schwannoma).
  • So, the final diagnosis was intradural primitive malignant melanoma.
  • Specific MRI sequences can eliminate adipose tissue tumor, but diagnosis between melanin and methemoglobin is still difficult.
  • According to the index of proliferation, a primitive central melanocytic lesion can be a meningeal melanocytoma (considered as benign) or a primitive malignant melanoma.
  • These tumors show identical protein expressions in immunohistochemistry, and their prognosis is very variable (some long-term remissions are reported for malignant melanomas and fast disseminations are described for meningeal melanocytomas treated by sub-total surgery).
  • The L3/L4 foramen scalloping is unusual for a malignant lesion with theoretic high-speed development.
  • The histological features of malignant lesion with benign clinical features lead to interrogation upon the actual pathologic classification.
  • [MeSH-major] Melanoma / pathology. Spinal Neoplasms / pathology. Spinal Nerve Roots / pathology
  • [MeSH-minor] Adult. Antigens, Neoplasm. Cell Proliferation. Fatal Outcome. Female. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Melanins / metabolism. Melanoma-Specific Antigens. Neoplasm Proteins / metabolism. Neurologic Examination. S100 Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840974.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanins; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


43. Situm M, Bulat V, Buljan M, Puljiz Z, Situm V, Bolanca Z: Senile lentigo--cosmetic or medical issue of the elderly population. Coll Antropol; 2010 Apr;34 Suppl 2:85-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Senile lentigo or age spots are hyperpigmented macules of skin that occur in irregular shapes, appearing most commonly in the sun-exposed areas of the skin such as on the face and back of the hands.
  • Senile lentigo is a common component of photoaged skin and is seen most commonly after the age of 50.
  • There are many disscusions on whether senile lentigo represents a melanoma precursor, namely lentigo maligna melanoma and, if there is a need for a regular follow up in cases of multiple lesions.
  • Clinical observations sometimes report that in the location of the newly diagnosed melanoma, such lesion preexsisted.
  • However, the observation of the possible association of senile lentigo with the melanoma development makes us cautious in the assessment of this lesion.
  • [MeSH-major] Lentigo / pathology. Melanoma / pathology. Precancerous Conditions / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21302707.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Cosmetics
  •  go-up   go-down


44. Poehlein CH, Haley DP, Walker EB, Fox BA: Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts. Eur J Immunol; 2009 Nov;39(11):3121-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adding back TBM CD25(+) Treg to CD25(-) naïve and TBM donor T cells prior to reconstitution confirmed their suppressive role.
  • This effect may not be antigen-specific as three histologically distinct tumors generated CD25(+) Treg that could suppress the T-cell immune response to a melanoma vaccine.
  • Importantly, since ex vivo depletion of CD25(+) Treg from TBM spleen cells prior to reconstitution and vaccination fully restored the generation of therapeutic effector T cells, even in animals with established tumor burden, we have initiated a translational clinical trial of this strategy in patients with metastatic melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Feb 15;101(4):1645-52 [12406877.001]
  • [Cites] J Immunol. 2009 Sep 15;183(6):3682-9 [19692636.001]
  • [Cites] J Immunol. 2000 Oct 1;165(7):3656-62 [11034369.001]
  • [Cites] J Immunol. 2000 Oct 15;165(8):4246-53 [11035058.001]
  • [Cites] J Clin Invest. 2001 Sep;108(6):871-8 [11560956.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):931-6 [11792864.001]
  • [Cites] Immunity. 2002 Feb;16(2):311-23 [11869690.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4272-6 [11970966.001]
  • [Cites] J Immunother. 2002 May-Jun;25(3):207-17 [12000862.001]
  • [Cites] J Clin Invest. 2002 Jul;110(2):185-92 [12122110.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3914-9 [12124318.001]
  • [Cites] J Immunother. 2002 Jul-Aug;25(4):359-72 [12142559.001]
  • [Cites] Science. 2002 Oct 25;298(5594):850-4 [12242449.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):884-90 [12610189.001]
  • [Cites] Cancer Immun. 2002 Feb 22;2:1 [12747746.001]
  • [Cites] Eur J Immunol. 2003 Aug;33(8):2123-32 [12884286.001]
  • [Cites] Transpl Immunol. 2003 Jul-Sep;11(3-4):287-93 [12967782.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10878-83 [12949259.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6042-50 [14522933.001]
  • [Cites] Biochem Pharmacol. 2003 Dec 1;66(11):2185-91 [14609743.001]
  • [Cites] J Exp Med. 2003 Dec 15;198(12):1875-86 [14676299.001]
  • [Cites] Immunity. 2004 Jan;20(1):107-18 [14738769.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):668-80 [14760090.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5338-45 [15100273.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):771-82 [15381730.001]
  • [Cites] J Immunol. 1991 Jul 15;147(2):729-37 [1830072.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):796-807 [9053507.001]
  • [Cites] Semin Immunol. 1997 Dec;9(6):339-46 [9405262.001]
  • [Cites] Immunogenetics. 1998 Jul;48(2):116-24 [9634475.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 16;90(24):1894-900 [9862627.001]
  • [Cites] J Immunother. 2005 Jan-Feb;28(1):53-62 [15614045.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2346-57 [15800326.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5211-20 [15958566.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2018-25 [15914560.001]
  • [Cites] J Exp Med. 2005 Oct 3;202(7):907-12 [16203864.001]
  • [Cites] Adv Immunol. 2006;92:187-224 [17145305.001]
  • [Cites] J Immunother. 2007 Jan;30(1):123-9 [17198091.001]
  • [Cites] J Immunother. 2007 Feb-Mar;30(2):240-50 [17471171.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5256-61 [17875753.001]
  • [Cites] J Immunol. 2007 Oct 15;179(8):4969-78 [17911581.001]
  • [Cites] Nature. 2007 Nov 22;450(7169):566-9 [18033300.001]
  • [Cites] Semin Immunol. 2007 Oct;19(5):318-30 [18023361.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):178-87 [18172269.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1032-40 [18281535.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3156-67 [18483384.001]
  • [Cites] Curr Opin Immunol. 2008 Apr;20(2):241-6 [18508251.001]
  • [Cites] Blood. 2008 Aug 1;112(3):610-8 [18519811.001]
  • [Cites] Hum Gene Ther. 2000 Apr 10;11(6):839-50 [10779161.001]
  • (PMID = 19839008.001).
  • [ISSN] 1521-4141
  • [Journal-full-title] European journal of immunology
  • [ISO-abbreviation] Eur. J. Immunol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K22 CA127739-01A1; United States / NCI NIH HHS / CA / R01 CA092254; United States / NCI NIH HHS / CA / R01 CA080964; United States / NCI NIH HHS / CA / 1R01CA92254-01; United States / NCI NIH HHS / CA / K22CA127739; United States / NCI NIH HHS / CA / CA092254-01; United States / NCI NIH HHS / CA / R01 CA092254-01; United States / NCI NIH HHS / CA / R01 CA080964-09; United States / NCI NIH HHS / CA / CA127739-02; United States / NCI NIH HHS / CA / CA127739-01A1; United States / NCI NIH HHS / CA / K22 CA127739; United States / NCI NIH HHS / CA / 1R01CA80964; United States / NCI NIH HHS / CA / K22 CA127739-02; United States / NCI NIH HHS / CA / CA080964-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Interleukin-2 Receptor alpha Subunit
  • [Other-IDs] NLM/ NIHMS180123; NLM/ PMC2850261
  •  go-up   go-down


45. Pustisek N, Sikanić-Dugić N, Hirsl-Hećej V, Domljan ML: "Halo nevi" and UV radiation. Coll Antropol; 2010 Apr;34 Suppl 2:295-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Affected individuals frequently have multiple lesions which are usually localized on the back.
  • The etiology of halo nevi, association with malignant melanoma and the role of sun exposure in the development of halo nevi are discussed.
  • [MeSH-major] Autoimmune Diseases / complications. Melanoma / etiology. Nevus, Halo / etiology. Skin Neoplasms / etiology. Ultraviolet Rays / adverse effects


46. Ben Hadj Hamida F, Fezani M, Ben Amor H, Krifa F, Chaabani L, Khalfallah W, Yacoubi S, Ben Rayana N: [Orbital metastasis from cutaneous melanoma]. J Fr Ophtalmol; 2009 Jun;32(6):425-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Orbital metastasis from cutaneous melanoma].
  • PURPOSE: We report the case of a patient presenting with a one-sided orbital metastasis from a cutaneous melanoma, and analyze clinical features, diagnostic difficulties and prognosis of such metastasis.
  • The computed tomography (CT) disclosed an intraorbital mass with double tonality, rounded and well limited driving back the optic nerve and erasing the limits of the lateral rectus muscle.
  • It was then noted that a cutaneous melanoma of the left foot had been operated ten years before.
  • DISCUSSION: The cutaneous melanoma is a rare cause of orbital metastasis.
  • The diagnosis is often easy, when a primitive tumor is known, but it remains uncertain for a long time.
  • CONCLUSION: Orbital metastases from cutaneous melanoma are rare, generally occurring at the late stage of the disease with a life expectancy not passing one year.
  • [MeSH-major] Melanoma / secondary. Orbital Neoplasms / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19750592.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


47. Bickels J, Kollender Y, Wittig JC, Cohen N, Meller I, Malawer MM: Vacuum-assisted wound closure after resection of musculoskeletal tumors. Clin Orthop Relat Res; 2005 Dec;441:346-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study group included 15 women and eight men who had their wounds located at the back (two), pelvic girdle (11), thigh (eight), and leg (two).
  • This allowed primary closure in seven patients, primary closure with skin grafting in 14 patients, and healing by secondary intention in two patients.
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / surgery. Chondrosarcoma / surgery. Debridement. Female. Granulation Tissue. Humans. Male. Melanoma / pathology. Melanoma / surgery. Middle Aged. Retrospective Studies. Skin Neoplasms / secondary. Surgical Procedures, Operative / methods. Wound Healing

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16331025.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Pawlik TM, Erasmus JJ, Truong MT, Macapinlac H, Ross MI, Gershenwald JE: Acne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma. AJR Am J Roentgenol; 2006 Jul;187(1):W117-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma.
  • [MeSH-major] Acne Vulgaris / radionuclide imaging. Fluorodeoxyglucose F18. Melanoma / radionuclide imaging. Melanoma / secondary. Positron-Emission Tomography. Radiopharmaceuticals. Skin Neoplasms / pathology. Tomography, Emission-Computed
  • [MeSH-minor] Adult. Back. False Positive Reactions. Humans. Male

  • MedlinePlus Health Information. consumer health - Acne.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16794124.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


49. Kakutani K, Doita M, Nishida K, Miyamoto H, Kurosaka M: Radiculopathy due to malignant melanoma in the sacrum with unknown primary site. Eur Spine J; 2008 Sep;17 Suppl 2:S271-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiculopathy due to malignant melanoma in the sacrum with unknown primary site.
  • Melanoma is an interesting tumor, showing the appearance of metastasis without any trace of its primary lesion.
  • To report a very rare case of malignant melanoma in the sacrum with unknown primary origin.
  • The authors present a case of a 52-year-old man who was admitted with increasing lower back, left buttock, and left lower extremity pain, and dysuria.
  • The pathological diagnosis was malignant melanoma.
  • No obvious primary malignant melanoma was detected on the skin surface, on the oral or anal mucosa, or in the fundus oculi.
  • However the patient died nine months after initial diagnosis.
  • Malignant melanoma in the sacrum with an unknown primary site, showing S1 radiculopathy is reported for the first time.
  • The melanoma could have been a metastatic tumor of the sacrum, although the primary site was not detected.
  • The incidence of primary melanoma is increasing faster than any other cancer.
  • Thus treatment of patients with spinal metastasis of melanoma is an important challenge for orthopedic surgeons.
  • [MeSH-major] Melanoma / secondary. Neoplasms, Unknown Primary / pathology. Radiculopathy / etiology. Radiculopathy / pathology. Sacrum / pathology. Spinal Neoplasms / secondary
  • [MeSH-minor] Back Pain / etiology. Back Pain / pathology. Back Pain / physiopathology. Disease Progression. Drug Therapy. Fatal Outcome. Humans. Ilium / pathology. Ilium / radiography. Magnetic Resonance Imaging. Male. Middle Aged. Polyradiculopathy / etiology. Polyradiculopathy / pathology. Polyradiculopathy / physiopathology. Radiotherapy. Sacroiliac Joint / pathology. Sacroiliac Joint / radiography. Spinal Canal / pathology. Spinal Canal / radiography. Tomography, X-Ray Computed. Treatment Failure. Urination Disorders / etiology. Urination Disorders / pathology. Urination Disorders / physiopathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Melanoma Res. 2000 Feb;10(1):78-80 [10711643.001]
  • [Cites] Cancer. 1997 May 1;79(9):1816-21 [9129001.001]
  • [Cites] Cancer. 1970 Oct;26(4):816-20 [5506606.001]
  • [Cites] Oncology. 1972;26(2):265-70 [5049921.001]
  • [Cites] Cancer. 1972 Dec;30(6):1469-72 [4641758.001]
  • [Cites] Br J Surg. 1977 Nov;64(11):805-8 [588977.001]
  • [Cites] JAMA. 1979 Jan 26;241(4):381-3 [758556.001]
  • [Cites] Br Med J. 1979 Jun 9;1(6177):1530-3 [466103.001]
  • [Cites] Ann Surg. 1980 Jan;191(1):98-104 [7352784.001]
  • [Cites] Clin Orthop Relat Res. 1982 Sep;(169):95-102 [7105592.001]
  • [Cites] CA Cancer J Clin. 1991 Jul-Aug;41(4):201-26 [2049635.001]
  • [Cites] Cancer. 1991 Dec 15;68(12):2579-81 [1933805.001]
  • [Cites] Spine (Phila Pa 1976). 1995 Oct 1;20(19):2141-6 [8588172.001]
  • [Cites] Arch Phys Med Rehabil. 1996 Mar;77(3):307-9 [8600878.001]
  • [Cites] Br J Surg. 1967 Jul;54(7):651-8 [6026989.001]
  • (PMID = 18075762.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2525896
  •  go-up   go-down


50. Frable WJ: Error reduction and risk management in cytopathology. Semin Diagn Pathol; 2007 May;24(2):77-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, claims for "missed" cervical cytology specimens rank third, behind those for alleged misinterpretation of breast biopsies and pigmented skin lesions.
  • The severity of cervical cytology errors is high, at almost $700,000 per claim, surpassed only by those concerning melanoma.
  • Managing the "look-back" requirement of the Clinical Laboratory Amendments of 1988 (CLIA88) is also crucial; the need to issue amended reports as a consequence of that provision is quite rare.
  • [MeSH-minor] Aged. False Negative Reactions. Female. Humans. Middle Aged. Uterine Cervical Diseases / classification. Uterine Cervical Diseases / diagnosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633349.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Greco M, Mitri MD, Chiriacò F, Leo G, Brienza E, Maffia M: Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity. Cancer Lett; 2009 Oct 8;283(2):222-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity.
  • Currently clinical outcome in melanoma is not predictable by known serum biomarkers.
  • The only reliable tool for the diagnosis of this tumor is the histopathological assay after surgical removing.
  • We used a proteomic approach in order to identify novel non-invasive serum biomarkers of melanoma.
  • Significant increases of expression were found for transthyretin (TTR) and angiotensinogen (AGT) while vitamin D binding protein (DBP) expression was decreased in presence of melanoma.
  • Interestingly, protein expression came back to control values in stages I and II of the disease after 1 month since surgical removal of suspected melanoma.
  • In fact cancer cells release the alpha-N-acetylgalactosaminidase that can deglycosylate DBP thus interfering with the immune cascade response in which DBP is involved, leading to immunosuppression in melanoma patients.
  • Specific enzymatic activity of serum alpha-N-acetylgalactosaminidase was significantly increased in stage III melanoma patients, but not in early stages.
  • This enzymatic assay may provide a non-invasive way of evaluation of melanoma severity.
  • [MeSH-major] Biomarkers, Tumor / blood. Melanoma / blood. Skin Neoplasms / blood. alpha-N-Acetylgalactosaminidase / blood

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394758.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.2.1.49 / alpha-N-Acetylgalactosaminidase
  •  go-up   go-down


52. Lee TK, Atkins MS, King MA, Lau S, McLean DI: Counting moles automatically from back images. IEEE Trans Biomed Eng; 2005 Nov;52(11):1966-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Counting moles automatically from back images.
  • Density of moles is a strong predictor of malignant melanoma, therefore, enumeration of moles is often an integral part of many studies that look at malignant melanoma.
  • We have developed an unsupervised algorithm for segmenting and counting moles from two-dimensional color images of the back torso region, as part of a study to evaluate the effectiveness of sunscreen.
  • [MeSH-major] Algorithms. Artificial Intelligence. Back / pathology. Image Interpretation, Computer-Assisted / methods. Nevus, Pigmented / pathology. Pattern Recognition, Automated / methods. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285401.001).
  • [ISSN] 0018-9294
  • [Journal-full-title] IEEE transactions on bio-medical engineering
  • [ISO-abbreviation] IEEE Trans Biomed Eng
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. Aida K, Monia K, Ahlem S, Dominique HT, Becima F, Sylvie F, Ridha KM: Agminated Spitz nevi arising on a nevus spilus after chemotherapy. Pediatr Dermatol; 2010 Jul-Aug;27(4):411-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 3-year-old boy presented 3 months after the onset of a chemotherapy for a vesico-prostatic rhabdomyosarcoma, multiple pigmented papulo-nodules located on the face, neck, chest wall, and the higher back.
  • Histological examination of three excised nodules led to the diagnosis of Spitz nevus.
  • Our patient may have a high risk for melanoma since he has many criteria predisposing to this risk.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Nevus, Epithelioid and Spindle Cell / chemically induced. Prostatic Neoplasms / drug therapy. Rhabdomyosarcoma / drug therapy. Skin Neoplasms / chemically induced. Urinary Bladder Neoplasms / drug therapy


54. King R, Googe PB, Page RN, Mihm MC Jr: Melanocytic lesions associated with dermatofibromas: a spectrum of lesions ranging from junctional nevus to malignant melanoma in situ. Mod Pathol; 2005 Aug;18(8):1043-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanocytic lesions associated with dermatofibromas: a spectrum of lesions ranging from junctional nevus to malignant melanoma in situ.
  • A single case of lentiginous melanocytic hyperplasia overlying a dermatofibroma has been reported, however, nevi and melanoma have to the best of our knowledge, not been previously reported.
  • There were nine females and five males ranging in age from 30 to 64 years and anatomic sites included back (five), arm (six), flank (two), and leg (one).
  • The clinical diagnosis ranged from dermatofibroma to desmoplastic melanoma.
  • Histologically, the melanocytic lesions included junctional, compound, and dermal nevi, and malignant melanoma in situ.
  • In the case of the melanoma in situ, the dermatofibroma abutted the epidermis.
  • Awareness of this association will aid in the correct diagnosis, and immunohistochemical studies will help in the differentiation of these two cell populations.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Melanocytes / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, Neoplasm. Factor XIIIa / analysis. Female. Humans. Immunohistochemistry. MART-1 Antigen. Male. Melanoma / metabolism. Melanoma / pathology. Middle Aged. Neoplasm Proteins / analysis. Nevus / metabolism. Nevus / pathology. Proto-Oncogene Proteins c-kit / analysis. S100 Proteins / analysis

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803191.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins; 0 / S100 Proteins; EC 2.3.2.13 / Factor XIIIa; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


55. Schootman M, Aft R, Jeffe DB: An evaluation of lower-body functional limitations among long-term survivors of 11 different types of cancers. Cancer; 2009 Nov 15;115(22):5329-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differences in the prevalence of arthritis and lower-back pain and in access to medical care explained differences in lower-body functional limitation prevalence between controls and long-term breast, cervical, ovarian, and uterine cancer survivors.
  • Long-term bladder, colorectal, lymphoma, melanoma, and prostate cancer survivors were equally likely to report a lower-body functional limitation as controls.
  • CONCLUSIONS: Treatment of arthritis and lower-back pain and increasing access to medical care might help reduce the risk of lower-body functional limitations and improve quality of life among specific long-term cancer survivors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast. 2007 Jun;16(3):223-34 [17368903.001]
  • [Cites] J Womens Health (Larchmt). 2007 May;16(4):441-53 [17521246.001]
  • [Cites] J Clin Rheumatol. 2008 Apr;14(2):121 [18391686.001]
  • [Cites] Gen Hosp Psychiatry. 2008 Sep-Oct;30(5):407-13 [18774423.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1501-9 [18823716.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2000 Jan;55(1):M43-52 [10719772.001]
  • [Cites] Acta Oncol. 2000;39(2):173-80 [10859007.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2176-86 [11147587.001]
  • [Cites] Am J Epidemiol. 2002 Mar 15;155(6):507-15 [11882524.001]
  • [Cites] Psychosom Med. 2002 Jul-Aug;64(4):604-11 [12140350.001]
  • [Cites] Psychol Med. 2002 Aug;32(6):959-76 [12214795.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jan;12(1):4-13 [12540497.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2003 Jan;58(1):82-91 [12560417.001]
  • [Cites] Am J Epidemiol. 2003 Mar 15;157(6):539-45 [12631544.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2003 Dec;58(12):M1119-24 [14684709.001]
  • [Cites] Milbank Mem Fund Q Health Soc. 1976 Fall;54(4):439-67 [137366.001]
  • [Cites] J Gerontol. 1991 Nov;46(6):S345-57 [1940101.001]
  • [Cites] Soc Sci Med. 1994 Jan;38(1):1-14 [8146699.001]
  • [Cites] Med Care. 1996 Jan;34(1):73-84 [8551813.001]
  • [Cites] Soc Sci Med. 1999 Feb;48(4):445-69 [10075171.001]
  • [Cites] Maturitas. 1999 Jun 21;32(2):95-102 [10465377.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2005 Feb;60(2):207-12 [15814864.001]
  • [Cites] Arthritis Rheum. 2005 Apr;52(4):1274-82 [15818691.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8884-93 [16314649.001]
  • [Cites] J Am Geriatr Soc. 2005 Dec;53(12):2145-52 [16398900.001]
  • [Cites] Am J Epidemiol. 2006 Mar 1;163(5):450-8 [16421245.001]
  • [Cites] Ann Epidemiol. 2006 Mar;16(3):197-205 [16137893.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 19;98(8):521-9 [16622121.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2007 Jan;62(1):101-6 [17301046.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1824-31 [17488980.001]
  • [Cites] Eur J Health Econ. 2008 Jan;8 Suppl 2:S39-47 [18157733.001]
  • (PMID = 19676109.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112159-04; United States / NCI NIH HHS / CA / R01 CA137750; United States / NCI NIH HHS / CA / R01 CA112159; United States / NCI NIH HHS / CA / CA112159; United States / NCI NIH HHS / CA / P30 CA091842; United States / NCI NIH HHS / CA / CA91842; United States / NCI NIH HHS / CA / R01 CA112159-04
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS140669; NLM/ PMC2791371
  •  go-up   go-down


56. Cotter MA, Tristani-Firouzi P: Unsuitability of organ donation from a patient with a history of melanoma? J Am Acad Dermatol; 2006 Jun;54(6):1096-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unsuitability of organ donation from a patient with a history of melanoma?
  • A 52-year-old man with a history of melanoma presented to the emergency department with a massive intracranial hemorrhage.
  • Three years before presentation, the patient had undergone wide excision of a 3.75-mm melanoma from his back with sentinel lymph node biopsy, which yielded negative findings.
  • Although there are no specific guidelines for candidacy of organ donation from patients with a history of melanoma, there are several reports of donor-derived melanoma in organ transplant recipients, most with grave consequences.
  • [MeSH-major] Melanoma. Skin Neoplasms. Tissue Donors. Tissue and Organ Procurement / standards

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16713480.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Trost O, Danino AM, Kadlub N, Dalac S, Hervé C, Malka G: [What about sentinel node practice in early-staged cutaneous melanoma in France in 2003?]. Ann Chir Plast Esthet; 2005 Apr;50(2):99-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [What about sentinel node practice in early-staged cutaneous melanoma in France in 2003?].
  • [Transliterated title] Ganglion sentinelle dans le mélanome malin de bas stade: état des lieux en France en 2003.
  • AIM: The aim of this study was to establish the status of sentinel lymph node (SLN) biopsy procedure in cutaneous melanoma in France in 2002.
  • MATERIAL AND METHODS: This study was based upon the statistics of the main French melanoma centers.
  • The authors asked for the global attitude as far as SLN was concerned, number of cutaneous melanoma diagnosed during year 2002 and of SLN procedures performed, critters of inclusion and postoperative management in each case.
  • Answers were sent back by email.
  • Staffs performing SLN diagnosed a mean of 101 (8-400) melanoma and biopsied a mean of 21 (0-53) sentinel nodes.
  • The others diagnosed a mean of 151 (15-250) melanoma.
  • If 64% are performing SLN, more than 50% of the new melanoma are not included in the trial.
  • [MeSH-major] Melanoma / pathology. Sentinel Lymph Node Biopsy / statistics & numerical data. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820594.001).
  • [ISSN] 0294-1260
  • [Journal-full-title] Annales de chirurgie plastique et esthétique
  • [ISO-abbreviation] Ann Chir Plast Esthet
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  •  go-up   go-down


58. Jeong WC, Kim KJ, Ju HW, Back HK, Kim HK, Im SY, Lee HK: Cytoplasmic phospholipase A2 metabolites play a critical role in pulmonary tumor metastasis in mice. Anticancer Res; 2010 Sep;30(9):3421-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In this study, the effects of inhibitors of cPLA2, 5-lipoxygenase (5-LO), and cyclooxygenase (COX)-2 on pulmonary metastasis formation by B16F10 melanoma cells were investigated.
  • [MeSH-minor] Animals. Cyclooxygenase 2 / metabolism. Enzyme Inhibitors / pharmacology. Female. Lipoxygenase Inhibitors. Matrix Metalloproteinase Inhibitors. Melanoma, Experimental / secondary. Mice. Mice, Inbred C57BL. Neoplasm Invasiveness. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / enzymology. Neovascularization, Pathologic / pathology. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20944117.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Lipoxygenase Inhibitors; 0 / Matrix Metalloproteinase Inhibitors; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.1.1.4 / Phospholipases A2, Cytosolic
  •  go-up   go-down


59. Arumi-Uria M: Dysplastic nevus: the eye of the hurricane. J Cutan Pathol; 2008 Nov;35 Suppl 2:16-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • If we look back in history, we can find that in 1820, Norris had already described some very similarly pigmented lesions, also in a familial context, just as Cawley subsequently did in 1952.
  • Clark coined the term of dysplastic nevi for lesions presenting in patients with personal and family histories of malignant melanoma, having from 10 to 100 nevus lesions of a certain size, irregular shape and variable pigmentation of more than 5 mm.

  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976414.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 29
  •  go-up   go-down


60. Speroni L, Bustuoabad Vde L, Gasparri J, Chiaramoni NS, Taira MC, Ruggiero RA, Alonso Sdel V: Alternative site of implantation affects tumor malignancy and metastatic potential in mice: its comparison to the flank model. Cancer Biol Ther; 2009 Feb;8(4):375-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MC-C fibrosarcoma and B16F0 melanoma tumors were implanted intradermally in the dorsal region of the foot of mice.
  • Although foot tumors only reached 13% (MC-C) and 25% (B16F0) of the mean volume of flank tumors, a more malignant phenotype in terms of histology and survival rate was observed in this type of tumors.
  • [MeSH-major] Disease Models, Animal. Fibrosarcoma / pathology. Melanoma, Experimental / pathology. Neoplasm Invasiveness. Neoplasm Metastasis
  • [MeSH-minor] Animals. Back / pathology. Cell Line, Tumor. Disease Progression. Foot / pathology. Immunity, Cellular. Immunity, Innate. Mice. Neoplasm Transplantation / methods. Sheep. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2009 Feb;8(4):380-1 [19182538.001]
  • (PMID = 19197148.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Novak JF, Trnka F: Proenzyme therapy of cancer. Anticancer Res; 2005 Mar-Apr;25(2A):1157-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Protease-treated tumor cells contain a disrupted actin cytoskeleton and exhibit a loss of front-to-back polarity.
  • [MeSH-minor] Actin Cytoskeleton / drug effects. Actin Cytoskeleton / enzymology. Adherens Junctions / drug effects. Adherens Junctions / enzymology. Angiostatins / blood. Animals. Cattle. Cell Count. Cell Growth Processes / drug effects. Cell Line, Tumor. Cell Movement / drug effects. Dogs. Endostatins / blood. Female. Humans. Immunohistochemistry. Melanoma, Experimental / drug therapy. Melanoma, Experimental / enzymology. Mice. Mice, Inbred C57BL. Rats. Spheroids, Cellular. Tight Junctions / drug effects. Tight Junctions / enzymology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHYMOTRYPSIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Anticancer Res. 2005 May-Jun;25(3c):2599
  • (PMID = 15868959.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Endostatins; 86090-08-6 / Angiostatins; 9002-08-8 / Trypsinogen; 9035-75-0 / Chymotrypsinogen; EC 3.2.1.- / Amylases; EC 3.4.21.1 / Chymotrypsin; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


62. Hofmann MA, Sterry W, Trefzer U: Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit? Jpn J Clin Oncol; 2007 Mar;37(3):224-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
  • BACKGROUND: There is currently no chemotherapy or chemoimmunotherapy regimen that has shown impact on survival in patients with metastatic melanoma.
  • From a safety and practical point of view, there was no draw-back on treating patients in a non-intensive care unit.
  • CONCLUSION: This complex and highly toxic chemoimmunotherapeutic regimen should not be considered as standard therapy in patients with metastatic malignant melanoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINDESINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472972.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 0 / Interferon-alpha; 0 / Interleukin-2; 7GR28W0FJI / Dacarbazine; Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine
  •  go-up   go-down


63. Liegl B, Hornick JL, Fletcher CD: Primary cutaneous PEComa: distinctive clear cell lesions of skin. Am J Surg Pathol; 2008 Apr;32(4):608-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous PEComa: distinctive clear cell lesions of skin.
  • PEComas arising in somatic soft tissue or skin are rare.
  • Eight tumors were located on the limbs and 2 on the back.
  • Accurate recognition of this entity is essential because of potential misdiagnosis as malignant tumors, especially malignant melanoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Actins / analysis. Adolescent. Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / analysis. Calcium-Binding Proteins / analysis. Calmodulin-Binding Proteins / analysis. Dermis / pathology. Desmin / analysis. Diagnosis, Differential. Female. Giant Cells / pathology. Humans. Immunohistochemistry. Keratins / analysis. MART-1 Antigen. Male. Melanoma-Specific Antigens. Microfilament Proteins / analysis. Microphthalmia-Associated Transcription Factor / analysis. Middle Aged. Mitotic Index. Mucin-1 / analysis. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Subcutaneous Fat / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Dermatopathol. 2016 Feb;38(2):165-6 [26825164.001]
  • (PMID = 18277881.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Calmodulin-Binding Proteins; 0 / Desmin; 0 / MART-1 Antigen; 0 / MITF protein, human; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Microfilament Proteins; 0 / Microphthalmia-Associated Transcription Factor; 0 / Mucin-1; 0 / Neoplasm Proteins; 0 / calponin; 68238-35-7 / Keratins
  •  go-up   go-down


64. Mao ZG, Jiang CC, Yang F, Thorne RF, Hersey P, Zhang XD: TRAIL-induced apoptosis of human melanoma cells involves activation of caspase-4. Apoptosis; 2010 Oct;15(10):1211-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRAIL-induced apoptosis of human melanoma cells involves activation of caspase-4.
  • We report here that activation of caspase-4 is also involved in induction of apoptosis by TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells.
  • Notably, TRAIL triggered ER stress in melanoma cells as shown by up-regulation of the GRP78 protein and the spliced form of XBP-1 mRNA.
  • Importantly, inhibition of caspase-4 also partially blocked caspase-3 activation, suggesting that activation of caspase-4 may be positive feed-back mechanism to further enhance caspase-3 activation.
  • Collectively, these results show that activation of caspase-4 contributes to TRAIL-induced apoptosis and is associated with induction of ER stress by TRAIL in melanoma cells, and may have important implications for improving therapeutic efficacies of TRAIL in melanoma.
  • [MeSH-major] Apoptosis. Caspases, Initiator / metabolism. Melanoma / metabolism. Melanoma / pathology. TNF-Related Apoptosis-Inducing Ligand / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514521.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caspase Inhibitors; 0 / DNA-Binding Proteins; 0 / Heat-Shock Proteins; 0 / RNA, Small Interfering; 0 / Recombinant Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Transcription Factors; 0 / molecular chaperone GRP78; 0 / regulatory factor X transcription factors; EC 3.4.22.- / CASP4 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases, Initiator
  •  go-up   go-down


65. Sánchez MJ, Payer T, De Angelis R, Larrañaga N, Capocaccia R, Martinez C, CIBERESP Working Group: Cancer incidence and mortality in Spain: estimates and projections for the period 1981-2012. Ann Oncol; 2010 May;21 Suppl 3:iii30-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article provides estimates of cancer incidence in Spain for all cancers combined, with the single exception of non-melanoma skin cancer, and for major cancer sites over the period 1981-2006, with projections up to 2012.
  • PATIENTS AND METHODS: Estimates were obtained by applying the MIAMOD method, a statistical back-calculation approach, to derive incidence from mortality and relative survival data.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20427358.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Ardanaz A; Navarro C; Dorronsoro M; Pollán M; Molina ME
  •  go-up   go-down


66. Chien JC, Niu DM, Wang MS, Liu MT, Lirng JF, Chen SJ, Hwang B: Giant congenital melanocytic nevi in neonates: report of two cases. Pediatr Neonatol; 2010 Feb;51(1):61-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They increase the lifetime risk for malignant melanoma and neurological deficits, including leptomeningeal melanocytosis and epilepsy.
  • Case 1 presented with the largest nevus spreading across the posterior scalp, neck, chest wall, shoulder and upper back.
  • Case 2 presented with a huge nevus covering most parts of the lower abdomen, lower back, buttocks and bilateral upper thighs.
  • Here, we describe these two cases with congenital melanocytic nevi and review the literature about its clinical manifestations, outcomes, risks for malignant melanoma and neurocutaneous melanosis, and possible surgical interventions.
  • [MeSH-major] Nevus, Pigmented / congenital. Skin Neoplasms / congenital

  • Genetic Alliance. consumer health - Giant Congenital Nevi.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20225541.001).
  • [ISSN] 1875-9572
  • [Journal-full-title] Pediatrics and neonatology
  • [ISO-abbreviation] Pediatr Neonatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


67. De Giorgi V, Pinzani P, Salvianti F, Grazzini M, Orlando C, Lotti T, Pazzagli M, Massi D: Circulating benign nevus cells detected by ISET technique: warning for melanoma molecular diagnosis. Arch Dermatol; 2010 Oct;146(10):1120-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating benign nevus cells detected by ISET technique: warning for melanoma molecular diagnosis.
  • BACKGROUND: The notion that only malignant melanoma cells circulate and diffuse is shared by oncologists and pathologists.
  • OBSERVATIONS: During a study of identification of circulating melanoma cells using ISET, blood samples from a 69-year-old man with an atypical melanocytic lesion on his back were evaluated.
  • The morphological features were similar to those of the excised skin tissue specimen, and the patient was subsequently diagnosed as having a congenital melanocytic nevus.
  • CONCLUSION: The finding that benign nevus cells may circulate in blood brings into question the value of tyrosinase or other melanocytic markers as a molecular surrogate for circulating melanoma cells.
  • [MeSH-major] Cell Separation / methods. Melanoma / secondary. Molecular Diagnostic Techniques / methods. Neoplastic Cells, Circulating. Skin Neoplasms / pathology


68. Baastrup R, Sørensen M, Balstrøm T, Frederiksen K, Larsen CL, Tjønneland A, Overvad K, Raaschou-Nielsen O: Arsenic in drinking-water and risk for cancer in Denmark. Environ Health Perspect; 2008 Feb;116(2):231-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used a geographic information system to link addresses with water supply areas, then estimated individual exposure to arsenic using residential addresses back to 1970.
  • RESULTS: We found no significant association between exposure to arsenic and risk for cancers of the lung, bladder, liver, kidney, prostate, or colorectum, or melanoma skin cancer; however, the risk for non-melanoma skin cancer decreased with increasing exposure (incidence rate ratio = 0.88/microg/L average exposure; 95% confidence interval, 0.84-0.94).
  • Results adjusted for enrollment area showed no association with non-melanoma skin cancer.
  • CONCLUSIONS: The results indicate that exposure to low doses of arsenic might be associated with a reduced risk for skin cancer.

  • MedlinePlus Health Information. consumer health - Arsenic.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Epidemiology. 2000 Nov;11(6):673-9 [11055628.001]
  • [Cites] Scand J Public Health. 2007;35(4):432-41 [17786808.001]
  • [Cites] Int J Hyg Environ Health. 2002 Mar;205(1-2):85-94 [12018020.001]
  • [Cites] J Nutr. 2003 May;133(5 Suppl 1):1536S-8S [12730460.001]
  • [Cites] Am J Epidemiol. 2003 Dec 15;158(12):1193-201 [14652304.001]
  • [Cites] Am J Epidemiol. 2004 Feb 15;159(4):381-9 [14769642.001]
  • [Cites] Mol Cell Biochem. 2004 Jan;255(1-2):47-55 [14971645.001]
  • [Cites] Environ Health Perspect. 2004 Apr;112(5):599-603 [15064167.001]
  • [Cites] J Occup Environ Med. 2004 Mar;46(3):298-306 [15091293.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Aug 1;198(3):253-67 [15276404.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Aug 1;198(3):366-76 [15276416.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Aug 1;198(3):394-404 [15276419.001]
  • [Cites] Br J Cancer. 1986 Mar;53(3):399-405 [3964542.001]
  • [Cites] Lancet. 1988 Feb 20;1(8582):414-5 [2893213.001]
  • [Cites] Am J Epidemiol. 1989 Dec;130(6):1123-32 [2589305.001]
  • [Cites] Food Chem Toxicol. 1990 Jul;28(7):521-9 [2210525.001]
  • [Cites] Am J Epidemiol. 1995 Feb 1;141(3):198-209 [7840093.001]
  • [Cites] Am J Epidemiol. 1995 Mar 15;141(6):523-30 [7900719.001]
  • [Cites] Epidemiology. 1995 Jul;6(4):356-65 [7548341.001]
  • [Cites] Fundam Appl Toxicol. 1996 Feb;29(2):168-75 [8742312.001]
  • [Cites] Epidemiology. 1996 Mar;7(2):117-24 [8834549.001]
  • [Cites] Dan Med Bull. 1997 Nov;44(5):535-9 [9408738.001]
  • [Cites] Int J Epidemiol. 1998 Aug;27(4):561-9 [9758107.001]
  • [Cites] Environ Health Perspect. 1999 May;107(5):359-65 [10210691.001]
  • [Cites] Environ Health Perspect. 1999 Sep;107(9):705-10 [10464069.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Sep 1;207(2 Suppl):557-64 [15996700.001]
  • [Cites] J Health Popul Nutr. 2006 Jun;24(2):206-13 [17195561.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):920-8 [17565158.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Aug 1;222(3):258-63 [17109909.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Aug 1;222(3):271-80 [17306315.001]
  • [Cites] Am J Epidemiol. 2001 Mar 15;153(6):559-65 [11257063.001]
  • (PMID = 18288323.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; N712M78A8G / Arsenic
  • [Other-IDs] NLM/ PMC2235208
  • [Keywords] NOTNLM ; arsenic / cancer / cohort study / drinking-water / geographic information system
  •  go-up   go-down


69. Earle SA, Marshall DM: Management of giant congenital nevi with artificial skin substitutes in children. J Craniofac Surg; 2005 Sep;16(5):904-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of giant congenital nevi with artificial skin substitutes in children.
  • Giant congenital nevi are one of several skin conditions in the pediatric patient population whose treatment leaves the patient with large skin defects.
  • The giant congenital nevus is a rare pigmented skin lesion that covers large skin areas or affects any major or difficult-to-treat region of the body, such as the face.
  • Congenital nevi should be excised fully because of the increased risk for malignant transformation to melanoma, as well as cosmetic considerations.
  • Traditionally these defects have been repaired with split-thickness skin grafts, full-thickness skin grafts, the use of tissue expanders, and a variety of flaps.
  • Recently, new methods have been developed for the closure of large skin defects in pediatric patients with the use of artificial skin substitutes.
  • [MeSH-major] Nevus, Pigmented / congenital. Skin Neoplasms / congenital. Skin, Artificial
  • [MeSH-minor] Back. Child. Cicatrix / prevention & control. Contracture / prevention & control. Epithelial Cells / transplantation. Female. Humans. Male. Melanosis / congenital. Neurocutaneous Syndromes / congenital. Pelvis. Skin Transplantation. Thigh. Tissue and Organ Harvesting. Transplantation, Autologous

  • Genetic Alliance. consumer health - Giant Congenital Nevi.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16192880.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. LaVigne EA, Oliveria SA, Dusza SW, Geller AC, Halpern AC, Marghoob AA: Clinical and dermoscopic changes in common melanocytic nevi in school children: the Framingham school nevus study. Dermatology; 2005;211(3):234-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Nevi are potential precursors of malignant melanoma and are important risk factors for the development of the disease.
  • METHODS: Digital photographs and dermoscopic images of the back of subjects were compared at baseline and 1-year follow-up to assess changes in nevi counts and in clinical and dermoscopic features of index nevi.
  • [MeSH-major] Nevus, Pigmented / diagnosis. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 16205068.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


71. Repertinger S, Wang J, Adickes E, Sarma DP: Melanoma in-situ arising in seborrheic keratosis: a case report. Cases J; 2008;1(1):263
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma in-situ arising in seborrheic keratosis: a case report.
  • BACKGROUND: Seborrheic keratosis is a very common benign skin tumor in man.
  • Melanoma is rare but is the most dreaded of all malignant skin tumors.
  • A melanoma arising in a seborrheic keratosis is distinctly rare.
  • CASE PRESENTATION: An-86-year-old male with a history of multiple actinic keratoses and seborrheic keratoses of the head and trunk presented with a mid-back skin lesion.
  • We interpreted this lesion as a melanoma in-situ arising within a seborrheic keratosis.
  • We urge that all such lesions be examined by the pathologist to avoid missing another concomitant malignant lesion such as melanoma which needs adequate resection and close follow-up.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Australas J Dermatol. 2006 May;47(2):109-13 [16637806.001]
  • [Cites] J Am Acad Dermatol. 2000 May;42(5 Pt 1):831-3 [10775864.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 1):559-61 [15056152.001]
  • [Cites] Am J Dermatopathol. 1996 Jun;18(3):278-82 [8806962.001]
  • (PMID = 18947402.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2577645
  •  go-up   go-down


72. Roarke MC, Ram P, Nguyen BD: Utility of SPECT/CT in preoperative planning for sentinel lymph node biopsy in melanoma and head/neck carcinoma: three illustrative cases. Clin Nucl Med; 2007 Jun;32(6):464-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of SPECT/CT in preoperative planning for sentinel lymph node biopsy in melanoma and head/neck carcinoma: three illustrative cases.
  • [MeSH-major] Head and Neck Neoplasms / radiography. Head and Neck Neoplasms / radionuclide imaging. Melanoma / radiography. Melanoma / radionuclide imaging. Skin Neoplasms / radiography. Skin Neoplasms / radionuclide imaging. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Back. Diagnosis, Differential. Humans. Male. Middle Aged. Sentinel Lymph Node Biopsy


73. Nguyen BD: Scintigraphic imaging of a nuchal sentinel node. Clin Nucl Med; 2005 May;30(5):347-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The author presents a case of upper back melanoma with unusual nuchal sentinel node demonstrated by technetium-99m filtered sulfur colloid scintigraphy.
  • [MeSH-major] Lymph Nodes / radionuclide imaging. Melanoma / radionuclide imaging. Melanoma / secondary. Neck / radionuclide imaging. Skin Neoplasms / radionuclide imaging. Technetium Tc 99m Sulfur Colloid

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827411.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid
  •  go-up   go-down


74. Moehrle M, Dietrich H, Patz CD, Häfner HM: Sun protection by red wine? J Dtsch Dermatol Ges; 2009 Jan;7(1):29-32, 29-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: There is increasing evidence that polyphenols, antioxidants from plants such as green tea or grapes, may impair the UV-induced erythema reaction as well as carcinogenesis and metastasis of melanoma and epithelial skin cancer.
  • Irradiation was carried out prior to and immediately following 20 minutes of occlusive application of red wine as well as 12 % alcohol to the back.

  • MedlinePlus Health Information. consumer health - Sun Exposure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18673407.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols
  •  go-up   go-down


75. Buljan M, Situm M, Tomas D, Cavka V, Poduje S, Gasparov S: A case report of an unrecognized nevoid melanoma in a young woman--clinicopathological diagnostic challenge. Coll Antropol; 2010 Apr;34 Suppl 2:307-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report of an unrecognized nevoid melanoma in a young woman--clinicopathological diagnostic challenge.
  • Nevoid melanoma is a rare form of melanoma histologically resembling benign melanocytic nevi and may be overlooked in routine histological sections.
  • Authors are presenting a case of a 31-year-old woman who presented with bizarre pigmented skin lesions in the area of the postoperative scar on the back where, 6 years earlier, a "nevus pigmentosus epidermo-dermalis" was excised and hystologically confirmed in outer institution.
  • The lesions were surgically removed and histopathological findings were characteristic for nevoid melanoma.
  • Additionally, specimen of primary removed lesion was reexamined and primary nevoid melanoma was then recognized, therefore indicating that the lesions our patient presented with are nevoid melanoma recidivisms.
  • Extensive diagnostic procedures showed no signs of melanoma dissemination.
  • The lesions were excised and new nevoid melanoma recidivism was confirmed.
  • The patient remained under the regular follow up and, almost 9 years after the removal of primary nevoid melanoma, followed by two cutaneous recidivisms, remains disease-free.
  • This case aims to highlight the problematic area in the analysis of pigmented skin lesions where nevoid melanoma represents one of the clinical and pathological diagnostic challenges.
  • [MeSH-major] Melanoma / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21305748.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Croatia
  •  go-up   go-down


76. Ambros-Rudolph CM, Hofmann-Wellenhof R, Richtig E, Müller-Fürstner M, Soyer HP, Kerl H: Malignant melanoma in marathon runners. Arch Dermatol; 2006 Nov;142(11):1471-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma in marathon runners.
  • Over the past decade, we observed 8 ultramarathon runners with malignant melanoma.
  • To further evaluate risk factors for malignant melanoma in marathon runners, we examined anamnestic, phenotypic, sun-related, and clinical variables in 210 athletes and compared them with those of an age- and sex-matched control group.
  • OBSERVATIONS: Although control subjects exhibited higher sun sensitivity and more common melanocytic nevi, marathon runners presented with more atypical melanocytic nevi, solar lentigines, and lesions suggestive of nonmelanoma skin cancer.
  • During exercising, most runners wore shorts (96.7%) and shirts (98.6%) that would not or would only partially cover their back and extremities.
  • CONCLUSIONS: Compared with a representative control group, marathon runners presented with an increased risk for malignant melanoma and nonmelanoma skin cancer.
  • [MeSH-major] Melanoma / epidemiology. Running. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17116838.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sunscreening Agents
  •  go-up   go-down


77. Carrera C, Segura S, Palou J, Puig S, Segura J, Martí RM, Malvehy J: Seborrheic keratosislike melanoma with folliculotropism. Arch Dermatol; 2007 Mar;143(3):373-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seborrheic keratosislike melanoma with folliculotropism.
  • BACKGROUND: Seborrheic keratosislike melanoma could be one of the most problematic melanoma simulators, and it may be incorrectly treated by electrocautery or cryotherapy.
  • OBSERVATIONS: A 34-year-old man was seen for a conspicuous pigmented lesion on his back that clinically resembled a seborrheic keratosis because of the presence of multiple comedolike openings.
  • Findings from dermoscopic examination showed distinct melanoma criteria (atypical pigmented network, asymmetric globules and dots, and a blue-whitish veil), in addition to multiple comedolike openings.
  • Histopathological examination confirmed a peculiar melanoma variant characterized by prominent folliculotropism and minimal radial spreading.
  • This tumor was not associated with chronic sun-damaged skin.
  • CONCLUSION: Dermoscopy was useful in identifying a particular case of seborrheic keratosislike melanoma with folliculotropism, thus avoiding incorrect treatment.
  • [MeSH-major] Melanoma / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17372102.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Bishop JN, Bataille V, Gavin A, Lens M, Marsden J, Mathews T, Wheelhouse C: The prevention, diagnosis, referral and management of melanoma of the skin: concise guidelines. Clin Med (Lond); 2007 Jun;7(3):283-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevention, diagnosis, referral and management of melanoma of the skin: concise guidelines.
  • Melanoma of the skin is an increasingly common tumour, which often has a slow early growth rate during which curable lesions may be detected and removed.
  • Physicians therefore have the potential to reduce mortality and this guideline is intended to promote early diagnosis of melanoma.
  • The most common risk factors are pale sun-sensitive skin and the presence of increased numbers of melanocytic naevi (moles).
  • Melanoma is more common in women than men; the mean age of onset is 50 years; and a fifth of cases occur in young adults.
  • In the UK population the most common sites are on the lower leg in women, and on the back in men.
  • The predictors of melanoma are progressive change in the shape, size and colour of moles.
  • This guideline provides a series of photographs of moles, melanomas and other skin lesions, which may resemble melanomas.
  • [MeSH-major] Melanoma / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633952.001).
  • [ISSN] 1470-2118
  • [Journal-full-title] Clinical medicine (London, England)
  • [ISO-abbreviation] Clin Med (Lond)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 9
  •  go-up   go-down


79. Yarak S, Ogawa MM, Hirata S, de Almeida FA: Prevalence of acquired melanocytic naevi in Brazilian schoolchildren. Clin Exp Dermatol; 2010 Aug;35(6):581-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The prevalence of acquired melanocytic naevi (AMN) is one of the most important known risk factors for malignant melanoma (MM) in homogeneous white populations.
  • The number of AMN was higher on sun-exposed body sites, such as shoulders, thorax/upper abdomen, face/ears and back.
  • A high number of AMN was associated with lighter skin type, greater sun exposure, age, number of sunburns and presence of freckles.
  • [MeSH-major] Melanoma / epidemiology. Nevus, Pigmented / epidemiology. Skin Neoplasms / epidemiology. Sunlight / adverse effects
  • [MeSH-minor] Adolescent. Brazil / epidemiology. Child. Child, Preschool. Cross-Sectional Studies. Eye Color. Female. Hair Color. Humans. Male. Prevalence. Risk Factors. Skin Pigmentation. Sunburn / complications. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19874377.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


80. Siddaraju N, Yaranal PJ, Mishra MM, Soundararaghavan J: Fine needle aspiration cytology in recurrent amelanotic melanoma: a case report. Acta Cytol; 2007 Sep-Oct;51(5):829-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology in recurrent amelanotic melanoma: a case report.
  • BACKGROUND: Amelanotic melanoma can mimic a wide variety of epithelial and nonepithelial malignant tumors.
  • Varied cytomorphology of melanoma has been described on exfoliative and fine needle aspiration cytology (FNAC).
  • We report a case of recurrent amelanotic melanoma to highlight its varied cytomorphologic features, which may cause diagnostic problems on cytologic and on histologic examinations.
  • CASE: A 63-year-old male presented with nodular swellings in the right anterior chest wall, right axilla and back.
  • FNAC revealed malignant cells with highly varied morphology with plasmacytoid and pleomorphic malignant cells with occasional fibrocollagenous tissue strands showing adherent neoplastic cells.
  • A cytologic diagnosis of pleomorphic malignant tumor was suggested, and the original histologic slides were reviewed; they showed a striking alveolar pattern that vaguely resembled an alveolar rhabdomyosarcoma.
  • A final diagnosis of amelanotic melanoma was made.
  • CONCLUSION: Awareness of the highly varied cytomorphology of amelanotic melanoma minimizes the diagnostic difficulty on fine needle aspiration smears.
  • [MeSH-major] Melanoma, Amelanotic / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17910357.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Braun-Falco M, Friedrichson E, Ring J: Subepidermal cleft formation as a diagnostic marker for cutaneous malignant melanoma. Hum Pathol; 2005 Apr;36(4):412-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subepidermal cleft formation as a diagnostic marker for cutaneous malignant melanoma.
  • Cleft formation has been postulated as a clue to the histopathological diagnosis of malignant melanoma (MM).
  • The presence of clefts was not associated with age or sex of the patients, but showed a slight predilection for the back, a slightly higher prevalence in superficial spreading type of MM and for tumors with a Breslow thickness between 1 and 2 mm.
  • [MeSH-major] Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biomarkers. Diagnosis, Differential. Female. Humans. Male. Nevus, Pigmented / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2006 Jul;37(7):919-20 [16784994.001]
  • [CommentIn] Hum Pathol. 2006 Feb;37(2):246; author reply 247 [16426927.001]
  • (PMID = 15892003.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


82. Khayyata S, Bentley G, Fregene TA, Al-Abbadi M: Retroperitoneal extramedullary anaplastic plasmacytoma masquerading as sarcoma: Report of a case with an unusual presentation and imprint smears. Acta Cytol; 2007 May-Jun;51(3):434-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, paying attention to cytologic imprint smears can give valuable clues to the correct diagnosis.
  • CASE: A 73-year-old male was admitted to our hospital with a recent history of back pain.
  • The initial pathologic evaluation revealed a high grade pleomorphic neoplasm that failed to express multiple epithelial, mesenchymal, lymphoid and melanoma immunohistochemical markers.
  • CONCLUSION: Performing cytologic imprint smears on fresh tissue material may help in making the correct diagnosis and is highly recommended.
  • [MeSH-major] Plasmacytoma / diagnosis. Plasmacytoma / pathology. Retroperitoneal Neoplasms / diagnosis. Retroperitoneal Neoplasms / pathology. Sarcoma / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor. Cytoplasm / pathology. Diagnosis, Differential. Fatal Outcome. Humans. Immunophenotyping. Male. Specimen Handling

  • Genetic Alliance. consumer health - Plasmacytoma anaplastic.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536549.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


83. Vano-Galvan S, de las Heras E, Aguayo-Leyva I, Jaen P: Dermatoscopy for in vivo diagnosis of malignant melanoma. Aust Fam Physician; 2009 Jun;38(6):420-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatoscopy for in vivo diagnosis of malignant melanoma.
  • Clinically, a 12 mm long, slightly elevated, brown lesion with variegate pigmentation was observed on his back.
  • [MeSH-major] Dermoscopy. Melanoma / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19521586.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


84. Lee EY, Williamson R, Watt P, Hughes MC, Green AC, Whiteman DC: Sun exposure and host phenotype as predictors of cutaneous melanoma associated with neval remnants or dermal elastosis. Int J Cancer; 2006 Aug 1;119(3):636-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sun exposure and host phenotype as predictors of cutaneous melanoma associated with neval remnants or dermal elastosis.
  • Two histological characteristics of melanoma consistent with these divergent origins are dermal elastosis in adjacent skin and neval remnants contiguous with the tumor, respectively.
  • To further explore causal heterogeneity in melanoma, we compared sun exposure histories and phenotypic characteristics among a population-based sample of patients newly diagnosed with cutaneous melanoma with and without contiguous neval remnants or dermal elastosis.
  • Tissue blocks were obtained for 141 patients: 53 with superficial spreading melanoma (SSM) of the back, 42 with SSM of head and neck (H & N), and 39 and 7 with lentigo maligna/lentigo maligna melanoma (LM/LMM) of the H & N and back, respectively.
  • Melanomas of the H & N were less likely than those on back to have neval remnants (adjusted OR 0.6, 95% CI 0.3-1.4), but were significantly more likely to have dermal elastosis (adjusted OR 9.3, 95% CI 3.5-25).
  • Less marked associations were observed for melanomas of the back.
  • High levels of sun exposure strongly predicted dermal elastosis for H & N melanomas (OR 22.5, 95% CI 2.1-245), but not for melanomas of the back (OR 2.1, 95% CI 0.4-11).
  • [MeSH-major] Elastic Tissue / pathology. Melanoma / etiology. Nevus / complications. Skin Diseases / complications. Skin Neoplasms / etiology. Sunlight / adverse effects
  • [MeSH-minor] Age Factors. Back. Female. Head and Neck Neoplasms / etiology. Humans. Hutchinson's Melanotic Freckle / etiology. Male. Middle Aged. Odds Ratio. Skin / pathology. Skin / radiation effects

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16572428.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA88363
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


85. Scope A, Dusza SW, Halpern AC, Rabinovitz H, Braun RP, Zalaudek I, Argenziano G, Marghoob AA: The "ugly duckling" sign: agreement between observers. Arch Dermatol; 2008 Jan;144(1):58-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To assess whether multiple observers can identify the same pigmented lesion(s) as being different from a patient's other moles ("ugly duckling" [UD] sign) and to explore whether the UD sign is sensitive for melanoma detection.
  • DESIGN: Baseline back images of 12 patients were obtained from a database of standardized patient images.
  • All patients had at least 8 atypical moles on the back, and in 5 patients, one of the lesions was a histologically confirmed melanoma.
  • The overview back images were supplemented with close-up clinical images of lesions.
  • Participants were asked to evaluate whether the images showed any lesions on the back that differed from other nevi.
  • The sensitivity of the UD sign for melanoma detection was 0.9 for the whole group, 1.0 for experts, 0.89 for general dermatologists, 0.88 for nurses, and 0.85 for nonclinicians.
  • The potential of the UD sign for melanoma screening should be further assessed.
  • [MeSH-major] Dysplastic Nevus Syndrome / pathology. Melanoma / pathology. Nevus, Pigmented / pathology. Precancerous Conditions / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Cell Transformation, Neoplastic / pathology. Cohort Studies. Confidence Intervals. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Observer Variation. Probability. Registries. Risk Assessment

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18209169.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Kefford R, Beith JM, Van Hazel GA, Millward M, Trotter JM, Wyld DK, Kusic R, Shreeniwas R, Morganti A, Ballmer A, Segal E, Nayler O, Clozel M: A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs; 2007 Jun;25(3):247-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma.
  • There is no effective systemic therapy for disseminated metastatic melanoma.
  • Data suggest that endothelin may play a role in pathophysiology of melanoma and that the dual endothelin receptor antagonist bosentan may have anti-tumor activity.
  • This multicenter, open-label, single-arm, prospective, proof-of-concept study assessed the effects of bosentan monotherapy (500 mg oral tablets, bid) on tumor response in patients with stage IV metastatic melanoma.
  • Among the 35 patients included in this study with stage IV metastatic melanoma, 21 (60%) were stage M1C, 10 (29%) stage M1B and 4 (11%) stage M1A (American Joint Committee on Cancer [AJCC] classification).
  • Nine patients (26%) had received prior therapy for stage IV melanoma.
  • The most frequent adverse events were typical for the underlying disease or known to be associated with bosentan: headache (43%), fatigue (34%), nausea (31%), back pain (23%) and abnormal hepatic function (23%).
  • Bosentan might have benefit in disease stabilization in certain patients with metastatic melanoma and deserves further investigation in combination with other anticancer drugs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endothelin Receptor Antagonists. Melanoma / drug therapy. Skin Neoplasms / drug therapy. Sulfonamides / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2004 Dec;123(6):1135-9 [15610525.001]
  • [Cites] J Card Fail. 2005 Feb;11(1):12-20 [15704058.001]
  • [Cites] Lancet Oncol. 2003 Dec;4(12):748-59 [14662431.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1118-25 [15020614.001]
  • [Cites] J Clin Invest. 2002 Aug;110(4):443-52 [12189238.001]
  • [Cites] J Invest Dermatol. 1995 Jul;105(1):32-7 [7615973.001]
  • [Cites] Hum Mol Genet. 1995 Nov;4(11):2089-96 [8589685.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):687-701 [15721476.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1436-43 [14973117.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3892-7 [8632985.001]
  • [Cites] Cell. 1994 Dec 30;79(7):1267-76 [8001159.001]
  • [Cites] Eur Heart J. 2004 Dec;25(24):2243-78 [15589643.001]
  • [Cites] Int J Cancer. 2000 Apr 15;86(2):182-7 [10738244.001]
  • [Cites] Virchows Arch. 2001 May;438(5):485-91 [11407477.001]
  • [Cites] Cell. 1994 Dec 30;79(7):1277-85 [8001160.001]
  • [Cites] Lab Invest. 2000 Nov;80(11):1681-9 [11092528.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] J Vasc Res. 2001 Nov-Dec;38(6):536-45 [11740152.001]
  • [Cites] Exp Biol Med (Maywood). 2006 Jun;231(6):1111-9 [16741059.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11496-500 [10500205.001]
  • (PMID = 17021960.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Endothelin Receptor Antagonists; 0 / RNA, Messenger; 0 / Receptors, Endothelin; 0 / Sulfonamides; 0 / Tablets; Q326023R30 / bosentan
  •  go-up   go-down


87. Piccolo D, Altamura D, Lozzi GP, Peris K: Blue-whitish veil-like structure as the primary dermoscopic feature of combined nevus. Dermatol Surg; 2006 Sep;32(9):1176-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The combined nevus is a clinical simulator of melanoma, and clinical examination alone can be inadequate to diagnose this melanocytic pigmented skin lesion.
  • We report two cases of combined nevi dermoscopically characterized by a diffuse blue-whitish pigmentation similar to the blue-whitish veil, suggesting the diagnosis of melanoma.
  • [MeSH-major] Dermoscopy / methods. Nevus, Blue / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Back. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Thigh

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16970701.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Campos-do-Carmo G, Ramos-e-Silva M, Rochael MC, Cuzzi T: Spitzoid melanoma: dermoscopic report and diagnostic discussion. Acta Dermatovenerol Croat; 2010;18(4):252-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spitzoid melanoma: dermoscopic report and diagnostic discussion.
  • He presented a pigmented asymptomatic lesion on the back of his right thigh.
  • Dermoscopic examination revealed uncommon aspects, highly suspect of nodular melanoma, in particular a blue-whitish veil, striae and asymmetric globules.
  • Microscopic findings showed an atypical spitzoid tumor, compatible with spitzoid melanoma.
  • In this report, the importance of dermoscopy as an auxiliary method in the early diagnosis of cutaneous melanomas is emphasized.
  • [MeSH-major] Dermoscopy. Melanoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Humans. Male. Nevus, Epithelioid and Spindle Cell / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21251441.001).
  • [ISSN] 1847-6538
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


89. Brod C, Schippert W, Breuninger H: Dysplastic nevus syndrome with development of multiple melanomas. A surgical concept for prophylaxis. J Dtsch Dermatol Ges; 2009 Sep;7(9):773-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The latter proved to be more efficient and was used to completely excise the skin of the back, as well as parts of the arms and chest in two sessions under general anesthesia.
  • [MeSH-major] Dysplastic Nevus Syndrome / prevention & control. Dysplastic Nevus Syndrome / surgery. Melanoma / prevention & control. Nevus / surgery. Precancerous Conditions / surgery. Skin Neoplasms / prevention & control


90. Azarpira N, Torabineghad S, Sepidbakht S, Rakei M, Bagheri MH: Cytologic findings in pigmented melanotic schwannoma: a case report. Acta Cytol; 2009 Jan-Feb;53(1):113-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: A 37-year-old man presented with an 8-month history of lower back pain with no stigmata of Carney's syndrome on physical examination.
  • CONCLUSION: PMS is a rare entity, and it is important to differentiate PMS from other pigmented tumors in the spinal canal, such as melanocytoma and malignant melanoma.
  • It should be included in the differential diagnosis to avoid overtreatment.
  • [MeSH-major] Neurilemmoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Melanins. Pigmentation

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19248566.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Melanins
  •  go-up   go-down


91. Shirley R, Uppal R, Vadodoria S, Powell B: Ultrasound-guided wire localisation for surgical excision of deep seated metastatic deposit of malignant melanoma. J Plast Reconstr Aesthet Surg; 2009 Oct;62(10):e411-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasound-guided wire localisation for surgical excision of deep seated metastatic deposit of malignant melanoma.
  • [MeSH-major] Melanoma / surgery. Skin Neoplasms / surgery. Soft Tissue Neoplasms / surgery. Ultrasonography, Interventional
  • [MeSH-minor] Back. Female. Groin. Humans. Lymph Node Excision. Middle Aged. Sentinel Lymph Node Biopsy. Thigh

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19213622.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


92. Hamdi M, Van Landuyt K, de Frene B, Roche N, Blondeel P, Monstrey S: The versatility of the inter-costal artery perforator (ICAP) flaps. J Plast Reconstr Aesthet Surg; 2006;59(6):644-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The indications were: immediate partial breast reconstruction in eight patients who had a quadrantectomy for breast cancer; midline back and sternal defects in three patients who had radical excisions for a dermatofibrosarcoma or malignant melanoma; and autologous breast augmentation (four bilateral and one unilateral flap) in five post-bariatric-surgery patients.
  • [MeSH-minor] Adolescent. Adult. Breast Neoplasms / surgery. Dermatofibrosarcoma / surgery. Female. Humans. Mammaplasty / methods. Ribs. Skin Neoplasms / surgery. Thorax / blood supply. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16716957.001).
  • [ISSN] 1748-6815
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


93. Kudriavtsev DV, Mardynskiĭ IuS, Kudriavtseva GT: [Gender, tumor localization and regional metastases as prognostic factors in combined and complex treatment of cutaneous melanoma]. Vopr Onkol; 2007;53(2):170-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gender, tumor localization and regional metastases as prognostic factors in combined and complex treatment of cutaneous melanoma].
  • Data on 373 patients treated for cutaneous melanoma were evaluated to test a hypothesis whether there is a correlation between mechanism of protection from ultraviolet radiation and gender.
  • Cutaneous melanoma of the extremities was identified in 63.2% of females and 26.6% of males (p<0.001) versus 26.1% and 54.0%, respectively, with tumors of the trunk (p<0.001).
  • [MeSH-major] Melanoma / secondary. Melanoma / therapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy
  • [MeSH-minor] Abdomen. Adult. Back. Extremities. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Retrospective Studies. Risk Factors. Sex Factors. Survival Analysis. Treatment Outcome. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17663170.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


94. Xiao JP, Xu GZ, Miao YJ, Wei WB, Hu SM, Tang X, Wang JZ, Wang GL: [Preliminary results of radiosurgery for uveal melanoma]. Zhonghua Zhong Liu Za Zhi; 2005 Apr;27(4):241-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preliminary results of radiosurgery for uveal melanoma].
  • OBJECTIVE: To evaluate the clinical value of stereotactic radiosurgery (SRS) for uveal melanoma.
  • METHODS: From Jan, 1996 to March, 2004, 16 patients with uveal melanoma were treated with SRS, two by one session (35 Gy, 25 Gy) and fourteen by fractionated SRS (30-55 Gy/2-4F/4-16D).
  • CONCLUSION: Fractionated radiosurgery is safe and effective for uveal melanoma.
  • It is indicated for lesions of limited size (longest diameter < 20 mm, depth < 15 mm) located in the posterior pole or behind the equator at the back of the eyeball.
  • [MeSH-major] Melanoma / surgery. Radiosurgery. Uveal Neoplasms / surgery

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15949429.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


95. Blizniukov OP, Smirnova EA: [Sclerosing epithelial fibrosarcoma: a clinico-morphological evaluation of 10 cases]. Vopr Onkol; 2009;55(5):586-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sclerosing epithelial fibrosarcoma is a malignant mesenchymal tumor (fibroblastic class).
  • Differentiated analysis of epithelioid fibrosarcoma may also be done by computed microscopy and immunomorphology using other tumor models consisting of light-cytoplasm epitheloid cells, mostly osteosarcoma, clear-cell renal carcinoma, melanoma, synovial sarcoma and clear-cell sarcoma of the tendon sheath and aponeurosis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Epithelioid Cells / pathology. Fibrosarcoma / diagnosis
  • [MeSH-minor] Abdomen. Adult. Back. Female. Humans. Leg. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Sclerosis. Thorax

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20020654.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


96. Chan YC, Giam YC: A retrospective cohort study of Southeast Asian patients with large congenital melanocytic nevi and the risk of melanoma development. J Am Acad Dermatol; 2006 May;54(5):778-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective cohort study of Southeast Asian patients with large congenital melanocytic nevi and the risk of melanoma development.
  • BACKGROUND: The lifetime risk of developing melanoma in Caucasian patients with large congenital melanocytic nevi (LCMN) is estimated to be between 4.5% and 10%.
  • Cohort studies of LCMN and the risk of melanoma development in an Asian population are not available.
  • OBJECTIVE: We sought to determine the risk of melanoma development in a retrospective cohort of patients presenting with LCMN to a dermatology tertiary referral center in Singapore from January 1989 to December 2004.
  • The most common sites were the back (54%), lower limb (28%), and abdomen (26%).
  • Magnetic resonance imaging of the head or thoracolumbar spine was performed in 7 patients with LCMN on the scalp/face or back, respectively; all produced normal findings.
  • Skin biopsies were done in 5 patients who had developed nodules; histology showed no evidence of malignancy.
  • The small sample size did not allow a precise estimate of the risk of melanoma development in our study population.
  • CONCLUSION: The risk of melanoma development in LCMN within a predominantly Southeast Asian cohort appears to be very low.
  • Hence, patient education, regular melanoma surveillance, and biopsy of suspicious lesions are very important.
  • [MeSH-major] Melanoma / etiology. Nevus, Pigmented / complications. Nevus, Pigmented / congenital. Skin Neoplasms / etiology


97. Vazmitel M, Michal M, Mukensnabl P, Kazakov DV: Melanoma associated with a dysplastic nevus: report of two cases with unusual sebocyte-like melanocytes in the nevus part of the lesion. Am J Dermatopathol; 2007 Dec;29(6):566-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma associated with a dysplastic nevus: report of two cases with unusual sebocyte-like melanocytes in the nevus part of the lesion.
  • We present two cases of melanoma arising in a dysplastic nevus that contained intradermal sebocyte-like melanocytes characterized by a scalloped dark-staining nucleus surrounded by the pale multivacuolated cytoplasm imitating sebaceous differentiation.
  • Location included the back and temporal area.
  • Microscopically, both cases had the following features in common: the melanoma in situ, which was of the superficially spreading type, was associated with a dysplastic compound nevus, in which the sebocyte-like cells were identified in the intradermal nevus part of the lesion.
  • [MeSH-major] Dysplastic Nevus Syndrome / pathology. Melanocytes / pathology. Melanoma / pathology. Sebum / cytology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18032954.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


98. Bardarov S, Michael CW, Lucas D, Pang Y, Pu RT: Fine-needle aspiration biopsy of metastatic malignant melanoma resembling a malignant peripheral nerve sheath tumor. Diagn Cytopathol; 2008 Oct;36(10):754-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy of metastatic malignant melanoma resembling a malignant peripheral nerve sheath tumor.
  • We report a case of metastatic malignant melanoma resembling a malignant peripheral sheath tumor, which posed a significant diagnostic challenge.
  • Five years ago the patient was diagnosed with melanoma on the back with Clark level of IV.
  • The melanoma was excised with clear margins and sentinel lymph nodes were negative.
  • Careful examination of patient's previous slides revealed an area of spindle cell melanoma adjacent to a nodular type melanoma.
  • Based on the patient's previous history, current clinico-pathologic presentation and immunohistochemical profile, the diagnosis of metastatic malignant melanoma resembling peripheral nerve sheath tumor was favored over the diagnosis of metastatic malignant spindle cell neoplasm of unknown primary site, which by itself is very rare clinical scenario.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Melanoma / diagnosis. Melanoma / secondary. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Lung / metabolism. Lung / pathology. Male. Prognosis. S100 Proteins / metabolism. Vimentin / metabolism


99. Molina-Garrido MJ, Mora A, Andrada E, Guillén-Ponce C, Cánovas V, Guirado-Risueño M, Pastor E, Molina MA, Molina MJ, Martín Hidalgo A, Carrato A: Multiple bone lesions resembling a metastatic origin. An unexpected diagnosis. Clin Transl Oncol; 2008 Apr;10(4):241-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple bone lesions resembling a metastatic origin. An unexpected diagnosis.
  • Lytic and blastic lesions have been associated to malignant tumours, such as solid cancer (breast cancer, renal cancer, prostate cancer, malignant melanoma or thyroid tumours).
  • [MeSH-major] Bone Neoplasms / secondary. Mastocytosis, Systemic / diagnosis. Mastocytosis, Systemic / physiopathology. Osteolysis / etiology
  • [MeSH-minor] Aged. Anemia / complications. Back Pain / etiology. Bone Density Conservation Agents / therapeutic use. Diagnosis, Differential. Diphosphonates / therapeutic use. Female. Humans. Hypertension / complications. Imidazoles / therapeutic use. Immunologic Factors / therapeutic use. Interferon-alpha / therapeutic use. Magnetic Resonance Imaging. Osteoporosis / complications. Osteoporosis / drug therapy. Radionuclide Imaging

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Rheumatol. 2005 Apr;11(2):105-8 [16357712.001]
  • [Cites] J Bone Joint Surg Am. 1993 Sep;75(9):1276-81 [8408149.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2496-506 [12456500.001]
  • [Cites] Acta Haematol. 1996;96(1):45-9 [8677761.001]
  • [Cites] Clin Nucl Med. 2005 May;30(5):363-4 [15827418.001]
  • [Cites] Leuk Res. 2004 Mar;28(3):249-57 [14687620.001]
  • [Cites] Ups J Med Sci. 2004;109 (1):49-56 [15124953.001]
  • [Cites] An Med Interna. 2004 Dec;21(12):593-6 [15628955.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3440-7 [17592153.001]
  • [Cites] Leuk Res. 2001 Jul;25(7):603-25 [11377686.001]
  • [Cites] Skeletal Radiol. 2004 Apr;33(4):230-3 [14740182.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1A):107-15 [15816526.001]
  • [Cites] Skeletal Radiol. 1998 Mar;27(3):119-26 [9554001.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1272-80 [8201389.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Jun;14 (3):659-87, vii [10909045.001]
  • [Cites] Br J Radiol. 2002;75 Suppl 1:A2-12 [12036828.001]
  • (PMID = 18411200.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 0 / Immunologic Factors; 0 / Interferon-alpha; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


100. Berner V, Liu H, Zhou Q, Alderson KL, Sun K, Weiss JM, Back TC, Longo DL, Blazar BR, Wiltrout RH, Welniak LA, Redelman D, Murphy WJ: IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med; 2007 Mar;13(3):354-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy.
  • Protective cell-mediated immune responses in cancer are critically dependent on T-helper type 1 (T(H)1) cytokines such as interferon-gamma (IFN-gamma).
  • We have previously shown that the combination of CD40 stimulation and interleukin-2 (IL-2) leads to synergistic antitumor responses in several models of advanced metastatic disease.
  • We now report that after this treatment and other immunotherapy regimens, the CD4+ T-cell population, in contrast to CD8+ T cells, did not significantly increase but rather exhibited a substantial level of apoptosis that was dependent on IFN-gamma.
  • Mice immunized with tumor cells and treated with an immunotherapy regimen that was initially protective were later unable to mount effective memory responses compared with immunized mice not receiving immunotherapy.
  • Immunotherapy given to tumor-bearing Ifngr-/- mice resulted in restoration of secondary responses.
  • Thus, although immunotherapeutic regimens inducing strong IFN-gamma responses can lead to successful early antitumor efficacy, they may also impair the development of durable antitumor responses.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Med. 2007 Mar;13(3):248-50 [17342116.001]
  • (PMID = 17334371.001).
  • [ISSN] 1078-8956
  • [Journal-full-title] Nature medicine
  • [ISO-abbreviation] Nat. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA095572; United States / NCI NIH HHS / CA / R01 CA095572-04A1; United States / NCRR NIH HHS / RR / P20 RR16464; United States / NCI NIH HHS / CA / R01 CA72669; United States / NCI NIH HHS / CA / R01 CA95572; United States / NCI NIH HHS / CO / N01-CO-12400; United States / NCI NIH HHS / CA / CA095572-04A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 82115-62-6 / Interferon-gamma
  •  go-up   go-down






Advertisement